WO2023122643A1 - Cd83 and allo- and autoimmune conditions - Google Patents
Cd83 and allo- and autoimmune conditions Download PDFInfo
- Publication number
- WO2023122643A1 WO2023122643A1 PCT/US2022/082106 US2022082106W WO2023122643A1 WO 2023122643 A1 WO2023122643 A1 WO 2023122643A1 US 2022082106 W US2022082106 W US 2022082106W WO 2023122643 A1 WO2023122643 A1 WO 2023122643A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- subject
- population
- gvhd
- expression
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title claims abstract description 18
- 101100438949 Mus musculus Cd83 gene Proteins 0.000 title 1
- 102100035793 CD83 antigen Human genes 0.000 claims abstract description 157
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 92
- 210000002865 immune cell Anatomy 0.000 claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 28
- 208000024908 graft versus host disease Diseases 0.000 claims description 121
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 75
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 230000001684 chronic effect Effects 0.000 claims description 54
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 49
- 230000001154 acute effect Effects 0.000 claims description 48
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 36
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 27
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 230000003325 follicular Effects 0.000 claims description 23
- 208000024891 symptom Diseases 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 17
- 230000000735 allogeneic effect Effects 0.000 claims description 16
- 239000012642 immune effector Substances 0.000 claims description 15
- 229940121354 immunomodulator Drugs 0.000 claims description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 14
- 238000002054 transplantation Methods 0.000 claims description 14
- 210000004964 innate lymphoid cell Anatomy 0.000 claims description 11
- 210000003289 regulatory T cell Anatomy 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- -1 abatacept Proteins 0.000 claims description 4
- 229960000548 alemtuzumab Drugs 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 3
- 229940074162 belumosudil Drugs 0.000 claims description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 3
- 229960001507 ibrutinib Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229960000215 ruxolitinib Drugs 0.000 claims description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 238000003559 RNA-seq method Methods 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960002923 denileukin diftitox Drugs 0.000 claims description 2
- 108010017271 denileukin diftitox Proteins 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229950010152 halofuginone Drugs 0.000 claims description 2
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
- 229960002340 pentostatin Drugs 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 60
- 230000005764 inhibitory process Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102100027207 CD27 antigen Human genes 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 5
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 208000001388 Opportunistic Infections Diseases 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010002961 Aplasia Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 210000004286 T(FH) Anatomy 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000919922 Homo sapiens Cortistatin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the application relates generally to materials and methods for identifying and/or treating subjects at risk of suffering from an allo- or autoimmune condition, such as Graft versus Host Disease (GvHD).
- GvHD Graft versus Host Disease
- Autoimmunity is an immune response to self-antigens, which results in the body attacking normal cells and tissues.
- autoimmune diseases There are more than 80 types of autoimmune diseases that present unique clinical symptoms and affect different parts of the body.
- alloimmunity is an immune response to antigens from different members of the same species. Alloimmunity is triggered primarily by differences in the major histocompatibility complex between individuals within a species. The body’s response to alloimmune conditions and autoimmune conditions mimics the response against infection, involving activation of immune cells, inflammation, and tissue damage.
- GvHD graft versus Host Disease
- HCT allogeneic hematopoietic cell transplantation
- GvHD is typically treated with immunosuppressive and cytotoxic drugs.
- a challenge in the field is that most patients are treated prophylactically to inhibit or prevent the onset of GvHD, resulting in many patients being subjected to immune suppressing therapies or cytotoxic therapies unnecessarily or for a longer period of time than needed.
- immune suppressing therapies or cytotoxic therapies unnecessarily or for a longer period of time than needed.
- the disclosure provides a method of treating or reducing the risk of developing an autoimmune condition in a subject in need thereof.
- the method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.
- the autoimmune condition is acute graft-versus- host disease (GvHD) and the population of immune cells in step (a) comprises CD4+ T cells.
- the method is performed within 30 days of the subject receiving allogeneic hematopoietic cell transplantation and, in various aspects, prior to the onset of acute GvHD symptoms.
- the condition is chronic GvHD and the population of immune cells in step (a) comprises CD19+ B cells and/or T helper follicular cells.
- the method is optionally performed after 60 days of the subject receiving allogeneic hematopoietic cell transplantation and, in various aspects, prior to the onset of chronic GvHD symptoms.
- the disclosure further provides a method of identifying a subject at risk of developing acute GvHD.
- the method comprises measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD.
- the disclosure also provides a method of identifying a subject at risk of developing chronic GvHD.
- the method comprises measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD.
- the method comprises measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
- Figure 1 A is a bar graph illustrating %CD83+ CD4+ T cells in subjects not suffering from acute GvHD and subjects suffering from Grade ll-IV acute GvHD.
- Figure 1C is a bar graph illustrating CD83 gMFI (geometric mean fluorescence intensity) by CD4+ T cells in subjects not suffering from acute GvHD and subjects suffering from Grade ll-IV acute GvHD.
- Figures 1 B and 1 D are a line graphs illustrating % sensitivity.
- Figures 2A-2B Earlier acute GvHD diagnosis is associated with increased CD4+ T cell CD83 expression.
- Figures 3A-3B Increased CD4+ T cell CD83 expression by day +100 is associated with reduced survival after alloHCT.
- Figure 3B is a line graph showing the overall survival of the alloHCT recipients based on diagnosis of grade ll-IV acute GVHD by day +100. Top line - no GvHD; bottom line - Grade ll-IV.
- Figures 4A and 4D illustrate %CD83+ cells (Figure 4A) and CD83 gMFI (geometric mean fluorescence intensity; Figure 4D) on B cells, T helper follicular cells (Tfh) and monocytes.
- Figures 4B, 4C, 4E, and 4F are ROC curves depicting %CD83 expression and geometric mean fluorescence intensity.
- FIG. 4G-4H shows the ( Figure 4G) %CD83 + and ( Figure 4H) CD83 gMFI among age-associated (ABC) (CD19 + , CD2T, CD11c + ), IgD* memory (CD19 + , IgD*, CD38
- FIGS 5A-5C Increased B cell or Tfh CD83 expression after day +100 is associated with reduced survival after alloHCT.
- a gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for B cells and Tfh, respectively.
- Figure 5C is a graph showing overall survival based on the diagnosis of chronic GVHD after day +100.
- Figures 6A-6C Auto-activated B cells from patients with chronic GvHD were stimulated with antihuman IgM and OP9-DL1 cells and cultured with anti-CD19 CAR T cells, anti-CD83 CAR T cells, or untransduced T cells for 72 hours.
- the CD83 CAR T cells eliminated the autoreactive CD83 positive B cells, but did not cause complete B cell aplasia observed with CD19 CAR T cell therapy.
- the disclosure is based, at least in part, on the surprising discovery that CD83 expression in various immune cells is an indicator of the onset of allo- or autoimmunity, thereby allowing a means for identifying subjects at risk of developing an alloimmune condition or autoimmune condition or identifying subjects in the very early stages of an allo- or autoimmune condition.
- the materials and methods described herein allow for more informed decisions as to whether and when to treat subjects with therapeutics effective against alloimmune and/or autoimmune conditions.
- CD83+ CD4+ T cells are increased among alloHCT recipients with grade ll-IV acute GVHD.
- CD83 expression is exceedingly low on regulatory T cells or CD8+ T cells, which are critical for durable immune tolerance and beneficial graft-versus-leukemia.
- the data presented herein demonstrate that the frequency of peripheral CD83+ CD4+ T cells and the intensity of CD83 expression are significantly increased among patients with grade ll-IV acute GvHD, and this correlates with disease onset.
- the materials and methods of the disclosure can inform the timing of intervention therapies (e g., CD83 CAR T administration or other anti-CD83 targeted therapy) to prevent or treat acute GvHD.
- intervention therapies e g., CD83 CAR T administration or other anti-CD83 targeted therapy
- the disclosure also is based, at least in part, on the discovery that CD83 expression on B cells and T helper follicular cells is increased upon chronic GvHD onset.
- Autoreactive B cells and T helper follicular (Tfh) cells (a subset of CD4+ helper T cells) contribute to chronic GVHD pathogenesis.
- the frequency of CD83+ B cells and Tfh, but not monocytes, were significantly increased among patients with chronic GVHD.
- CD83 expression on B cells and Tfh significantly correlated with chronic GVHD onset.
- low CD83 expression on either B cells or Tfh was determined to be associated with a significant survival advantage after alloHCT.
- CD83 expression on B cell and Tfh cells implicated in chronic GvHD, can serve as a biomarker for disease.
- the disclosure provides a method of treating or reducing the risk of developing an alloimmune or autoimmune condition in a subject in need thereof.
- the method comprises measuring CD83 in a population of immune cells from the subject and administering to the subject a CD83-targeted therapeutic.
- the condition is GvHD.
- the GvHD may be acute GvHD or may be chronic GvHD. While the symptoms of acute and chronic GvHD overlap, acute and chronic GvHD are immunologically distinct complications (e.g., complications of alloHCT).
- Acute GvHD is primarily mediated by alloreactive T cells.
- Acute GvHD is potentiated by early tissue damage during the conditioning regimens (e.g., radiation and/or chemotherapy) used to prepare patients to receive allogeneic hematopoietic cells. Further, disruption of the host gut microbiota further fuels alloreactivity by the lack of intestinal butyrate.
- Acute GvHD typically impacts the skin, gut, and liver and often occurs before day 100 post-transplant.
- Chronic GvHD stems from a unique triad of thymic impairment, auto- and alloantibody production by reactive B cells, and systemic tissue fibrosis.
- Chronic GvHD is a systemic disease affecting host mucocutaneous tissues, musculoskeletal system, gastrointestinal tract, liver, lungs, immune system, and cardiovascular system.
- Chronic GvHD typically occurs later after transplantation (e.g., after day 100 post alloHCT), and can essentially develop at any time, even decades after the procedure. Similar to acute GvHD, treatment of chronic GvHD requires the use of broadly immune suppressive medications. The ability to track chronic GvHD risk by the expression of CD83 on B cells and Tfh has robust clinical impact.
- the measuring step is performed prior to the onset of GvHD symptoms (i.e. , the subject is not suffering from one or more symptoms of GvHD or other allo- or autoimmune condition).
- GvHD symptoms i.e. , the subject is not suffering from one or more symptoms of GvHD or other allo- or autoimmune condition.
- Common symptoms of acute GvHD have been reported in the literature and include, but are not limited to, skin rash or reddening, discoloration of the skin and/or eyes (Jaundice), nausea, vomiting, diarrhea, and abdominal cramping.
- GvHD chronic GvHD
- common symptoms of chronic GvHD include, but are not limited to, skin rash or discoloration, tightness or thickening of the skin, discoloration of the eyes, vision changes, dry mouth or oral ulcers, difficulty swallowing, weight loss, abdominal swelling, shortness of breath, fatigue, muscle weakness or pain, sensitivity or tightness in the joints, cytopenia, or pericarditis.
- GvHD is monitored using a number of techniques, including (but not limited to) clinical examination, X-ray, CT scan, liver function tests, PET scan, MRI, capsule endoscopy, and biopsy.
- the method of the disclosure comprises measuring CD83 in a population of immune cells.
- Any suitable immune cell type may be utilized, including, e.g., CD4+ T cells, CD19+ B cells, and/or T helper follicular cells.
- Methods of identifying particular immune cell types are known in the art and include fluorescence-activated cell sorting (FACS).
- CD83 may be measured in a variety of ways.
- the method comprises measuring CD83 protein levels.
- Methods of determining protein levels or identifying expression of proteins in a target cell type are known in the art.
- CD83 protein levels are determined via western blot or dot blot analysis, immunohistochemistry (IHC, e.g., quantitative immunohistochemistry), flow cytometry, immunocytochemistry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunosorbent spot (ELISPOT; Coligan, J. E., et al., eds. (1995) Current Protocols in Immunology. Wiley, New York), radioimmunoassay, or chemiluminescent immunoassay.
- IHC immunohistochemistry
- ELISA enzyme-linked immunosorbent assay
- ELISPOT enzyme-linked immunosorbent spot
- CD83 protein levels also may be measured via geometric mean fluorescence intensity (gM Fl).
- CD83 may be quantified and monitored in real-time on cells of interest (e.g., CD4+ T cells, Tfh, or B cells) by, for example, peripheral blood draws and measured by flow cytometry.
- Flow cytometry is a feasible method of tracking various cell markers of GVHD, such as phosphorylated STAT3, as early as 21 days after allogeneic hematopoietic cell transplantation. See, e.g., Pidala, J., et al., (2021) Clinical Cancer Research. 27(10):2712-2722.
- measuring CD83 in a population of immune cells from the subject comprises measuring CD83 RNA levels.
- CD83 RNA is optionally measured via real time polymerase chain reaction (qRT-PCR) or RNA sequencing.
- qRT-PCR real time polymerase chain reaction
- RNA sequencing RNA sequencing.
- the sequence of CD83 is known in the art. See, e g., Genbank Accession Nos. NM_001040280 and NM_004233.
- CD83 protein levels may be expressed as a quantity or concentration of CD83 found in an immune cell population, or it may be expressed as a percentage of immune cells expressing CD83.
- the condition is acute GvHD
- the population of immune cells comprises CD4+ T cells.
- the measuring step optionally comprises detecting CD83 expression in at least 40% of CD4+ T cells in the population (e.g., at least 45%, at least 55%, or at least 60% of the cells in the population).
- the methodology may include (but does not require) flow cytometry, staining for live/dead cells (optionally including dump gate for CD19, CD16, CD14, etc.), CD3+, CD4+, and CD83+.
- CD83 expression in at least 40% of CD4+ T cells in a subject is associated with progression to Grade ll-IV acute GvHD.
- the measuring step comprises measuring CD83 using Geometric mean fluorescence intensity (gM Fl) and detecting a gMFI of at least 740.5.
- the method is performed within 30 days (e.g., within 25 days, within 20 days, within 15 days, within 10 days, or within 5 days) of the subject receiving a transplant, such as an allogeneic hematopoietic cell transplant.
- the condition is chronic GvHD and the population of immune cells comprises CD19+ B cells and/or T helper follicular cells.
- the disclosure contemplates a method comprising detecting CD83 expression in at least 19% of CD19+ B cells in the population (e.g., at least 20%, at least 25%, or at least 30% of CD19+ B cells) and/or measuring CD19+ B cell CD83 using gMFI and detecting a gMFI of at least 396.
- the disclosure also provides a method comprising detecting CD83 expression in at least 25% of T helper follicular cells (e.g., a least 30%, at least 35%, or at least 40%) in the population and/or measuring T helper follicular cell CD83 using gMFI and detecting a gMFI of at least 469.
- the method is performed after 60 days (e.g., after 75 days, after 90 days, or after 120 days) of the subject receiving a transplant (e.g., an allogeneic hematopoietic cell transplant).
- the method is performed prior to the onset of chronic GvHD symptoms.
- the method of the disclosure is suitable for use in the context of other autoimmune or alloimmune conditions.
- the condition is systemic lupus erythematosus (SLE), multiple sclerosis, sjogren’s syndrome, systemic sclerosis/scleroderma, inflammatory bowel disease, or rheumatoid arthritis.
- the term "treat,” as well as words related thereto, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
- the methods of treating a condition or disease of the present disclosure can provide any amount or any level of treatment.
- the treatment provided by the method may include treatment of one or more conditions or symptoms or signs of the disease being treated.
- the treatment method of the present disclosure may inhibit one or more symptoms of the disease.
- the treatment provided by the methods of the present disclosure may encompass slowing the progression of the disease.
- the term “treat” also encompasses prophylactic treatment of the disease.
- the treatment provided by the presently disclosed method may delay the onset or reoccurrence/relapse of the disease being prophylactically treated.
- the method delays the onset of the condition by 1 day, 2 days, 4 days, 6 days, 8 days, 10 days, 15 days, 30 days, two months, 4 months, 6 months, 1 year, 2 years, 4 years, or more.
- the prophylactic treatment encompasses reducing the risk of the condition being treated.
- the method reduces the risk of the condition 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or more.
- the term “therapeutically effective” refers to a sufficient quantity of a composition which ameliorates one or more causes or symptoms of a condition or disease.
- the method of treating the disease may be regarded as a method of inhibiting the disease or a symptom thereof.
- the term "inhibit” and words stemming therefrom may not be a 100% or complete inhibition or abrogation. Rather, there are varying degrees of inhibition of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
- the presently disclosed methods may inhibit the onset or re-occurrence of the condition or a symptom thereof to any amount or level.
- the inhibition provided by the methods is at least or about a 10% inhibition (e.g., at least or about a 20% inhibition, at least or about a 30% inhibition, at least or about a 40% inhibition, at least or about a 50% inhibition, at least or about a 60% inhibition, at least or about a 70% inhibition, at least or about a 80% inhibition, at least or about a 90% inhibition, at least or about a 95% inhibition, at least or about a 98% inhibition).
- a 10% inhibition e.g., at least or about a 20% inhibition, at least or about a 30% inhibition, at least or about a 40% inhibition, at least or about a 50% inhibition, at least or about a 60% inhibition, at least or about a 70% inhibition, at least or about a 80% inhibition, at least or about a 90% inhibition, at least or about a 95% inhibition, at least or about a 98% inhibition.
- the subject is a mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals from the order Carnivora, including Felines (cats) and Canines (dogs), mammals from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses).
- the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes).
- the mammal is a human.
- the method comprises administering to the subject a CD83-targeted therapeutic.
- a “CD83-targeted therapeutic” is a biological agent which provides a beneficial biological response with respect to treating or inhibiting the alloimmune or autoimmune condition and which specifically binds CD83 on the immune cell surface.
- An agent "specifically binds" to a target if it reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular target (e g., CD83) than it does with alternative targets (e.g., other cell surface proteins).
- a CD83-targeted therapeutic that specifically binds CD83 is one that binds CD83 with greater affinity, avidity, more readily, and/or with greater duration than it binds to other non-CD83 proteins. It is also understood that, for example, a CD83-targeted therapeutic which specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, "specific binding" does not necessarily require (although it can include) exclusive binding. In general, under designated assay conditions, a CD83- targeted therapeutic binds preferentially to a particular target molecule and does not bind in a significant amount to other components present in a test sample.
- a variety of assay formats may be used to select or characterize a CD83-targeted therapeutic.
- solid-phase ELISA immunoassay, immunoprecipitation, BIAcoreTM (GE Healthcare, Piscataway, NJ), fluorescence-activated cell sorting (FACS), OctetTM (ForteBio, Inc., Menlo Park, CA) and Western blot analysis are among many assays that may be used to characterize binding to CD83.
- BIAcoreTM GE Healthcare, Piscataway, NJ
- FACS fluorescence-activated cell sorting
- OctetTM FormeBio, Inc., Menlo Park, CA
- Western blot analysis are among many assays that may be used to characterize binding to CD83.
- a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 times background.
- a CD83-targeted therapeutic is said to "specifically bind" CD83 when the equilibrium dissociation constant (K D ) value is ⁇ 1 pM, such as ⁇ 100 nM, ⁇ 10 nM, ⁇ 100 pM, ⁇ 10 pM, or ⁇ 1 pM.
- the CD83-targeted therapeutic is an antibody that binds CD83, an antigen-binding antibody fragment that binds CD83 (e.g., an antigen binding portion of an antibody), or an antibody-like construct that binds CD83.
- the term "antibody” refers to an intact antigen-binding immunoglobulin.
- the antibody can be an IgA, IgD, IgE, IgG, or IgM antibody, including any one of lgG1 , lgG2, lgG3, or lgG4.
- an intact antibody comprises two full-length heavy chains and two full-length light chains.
- An antibody has a variable region and a constant region.
- variable region is generally about 100-110 or more amino acids, comprises three complementarity determining regions (CDRs), is primarily responsible for antigen recognition, and substantially varies among other antibodies that bind to different antigens. CDR sequences are described further below.
- a variable region typically comprises at least three heavy or light chain CDRs (Kabat et al., 1991 , Sequences of Proteins of Immunological Interest, Public Health Service N.I.H., Bethesda, Md.; see also Chothia and Lesk, 1987, J. Mol. Biol.
- framework region designated framework regions 1-4, FR1, FR2, FR3, and FR4, by Kabat et al., 1991; see also Chothia and Lesk, 1987, supra.
- the constant region allows the antibody to recruit cells and molecules of the immune system.
- Antibody-like constructs include those based on the full antibody structure and those that mimic antibody fragments which retain full antigen-binding capacity, e.g., scFvs, Fabs and VHH.
- the smallest antigen-binding fragment that retains its complete antigen binding site is the Fv fragment, which consists entirely of variable (V) regions.
- a soluble, flexible amino acid peptide linker is used to connect the V regions to a scFv (single chain fragment variable) fragment for stabilization of the molecule, or the constant (C) domains are added to the V regions to generate a Fab fragment (fragment, antigen-binding).
- Other antibody protein products include disulfide-bond stabilized scFv (ds-scFv), single chain Fab (scFab), as well as di- and multimeric antibody formats like dia-, tria- and tetra-bodies, or minibodies (miniAbs) that comprise different formats consisting of scFvs linked to oligomerization domains.
- VHH/VH of camelid heavy chain Abs as well as single domain Abs (sdAb).
- the building block that is most frequently used to create different antibody formats is the single-chain variable (V)-domain antibody fragment (scFv), which comprises V domains from the heavy and light chain (VH and VL domain) linked by a peptide linker of ⁇ 15 amino acid residues.
- V variable
- scFv single-chain variable-domain antibody fragment
- a peptibody or peptide-Fc fusion is yet another antibody-like construct protein product.
- the structure of a peptibody consists of a biologically active peptide grafted onto an Fc domain.
- Peptibodies are described in the art. See, e.g., Shimamoto et al., mAbs 4(5): 586-591 (2012).
- bispecific antibodies can be divided into five major classes: BsIgG, appended IgG, BsAb fragments (e.g., bispecific single chain antibodies), bispecific fusion proteins (e.g., antigen binding domains fused to an effector moiety), and BsAb conjugates. See, e.g., Spiess et al., Molecular Immunology 67(2) Part A: 97-106 (2015).
- bispecific antibody constructs also include, but are not limited to, tandem scFvs, bispecific T cell engager (BiTE®) format (a fusion protein consisting of two single-chain variable fragments (scFvs) joined by a linker), and Fab2 bispecifics.
- BiTE® bispecific T cell engager
- Fab2 bispecifics See, e.g., Chames & Baty, 2009, mAbs 1 [6]: 1-9; and Holliger & Hudson, 2005, Nature Biotechnology 23[9]: 1126-1136; Wu et al., 2007, Nature Biotechnology 25[11]: 1290-1297; Michaelson et al., 2009, mAbs 1[2]:128-141 ; International Patent Publication Nos.
- Multispecific antibody constructs such as trispecific antibody constructs (including three binding domains) or constructs having more than three (e.g. four, five, or more) specificities, also are contemplated.
- the antibodies may be a human antibody (i.e., having one or more variable and constant regions derived from human immunoglobulin sequences), humanized (i.e., have a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject), or chimeric (i.e., containing one or more regions from one antibody and one or more regions from one or more other antibodies).
- human antibody i.e., having one or more variable and constant regions derived from human immunoglobulin sequences
- humanized i.e., have a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and
- the CD83-targeted therapeutic is a nanobody, i.e., an antibody-like construct based on heavy-chain only antibodies (HcAbs) in camelids.
- HcAbs consist of just two heavy chains with a single variable domain (VHH).
- the nanobody of the disclosure comprises a VHH domain and one or two constant domains (e.g., CH2 and CH3).
- the antibody, antigen-binding fragment, or antibody-like construct is linked (or conjugated) to one or more moieties.
- the conjugate moiety may comprise a therapeutic agent, a radioactive isotope, a detectable label, a pharmacokinetic modifying moiety (e.g., human serum albumin), or a purifying moiety (e.g., tag).
- the conjugate moiety may be covalently attached either directly to the therapeutic or via a linker.
- the CD83-targeted therapeutic is an immune effector cell genetically modified to express a chimeric antigen receptor (CAR) polypeptide that selectively binds CD83.
- CAR chimeric antigen receptor
- Immune effector cells are preferably obtained from the subject to be treated (i.e., are autologous). However, in some embodiments, immune effector cell lines or donor effector cells (allogeneic) are used. Immune effector cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Immune effector cells can be obtained from blood collected from a subject using any number of techniques known to the skilled artisan, such as FicollTM separation. For example, cells from the circulating blood of an individual may be obtained by apheresis.
- immune effector cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation.
- a specific subpopulation of immune effector cells can be further isolated by positive or negative selection techniques.
- immune effector cells can be isolated using a combination of antibodies directed to surface markers unique to the positively selected cells, e.g., by incubation with antibody-conjugated beads for a time period sufficient for positive selection of the desired immune effector cells.
- enrichment of immune effector cells population can be accomplished by negative selection using a combination of antibodies directed to surface markers unique to the negatively selected cells.
- the immune effector cells may comprise any leukocyte involved in defending the body against infectious disease and foreign materials.
- the immune effector cells can comprise lymphocytes, monocytes, macrophages, dendritic cells, mast cells, neutrophils, basophils, eosinophils, or any combinations thereof.
- suitable immune effector cells include, but are not limited to Natural Killer (NK) cells, cytotoxic T cells, regulatory T cells, and innate lymphoid cells (types 1-3).
- T cells or T lymphocytes can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface.
- T helper cells TH cells
- helper cells assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surface.
- Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response.
- cytokines that regulate or assist in the active immune response.
- These cells can differentiate into one of several subtypes, including TH1 , TH2, TH3, TH7, TH9, or TFH, which secrete different
- Cytotoxic T cells destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T cells since they express the CDS glycoprotein at their surface. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells.
- Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon reexposure to their cognate antigen, thus providing the immune system with "memory" against past infections. Memory cells may be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO.
- Treg cells Regulatory T cells
- suppressor T cells dampen T cell-mediated immunity toward the end of an immune reaction and to suppress auto-reactive T cells that escaped the process of negative selection in the thymus.
- CD4+ Treg cells Two major classes of CD4+ Treg cells have been described-naturally occurring Treg cells and adaptive Treg cells.
- Natural killer T (NKT) cells (not to be confused with natural killer (NK) cells) bridge the adaptive immune system with the innate immune system.
- NKT natural killer T
- MHC major histocompatibility complex
- the T cells may comprise a mixture of CD4+ cells.
- the T cells are enriched for one or more subsets based on cell surface expression.
- the T cells are cytotoxic CD8+ T lymphocytes.
- the T cells comprise gamma-delta T cells, which possess a distinct T-cell receptor (TCR) having one gamma chain and one delta chain instead of alpha and beta chains.
- TCR T-cell receptor
- NK cells are CD56+CD3- large granular lymphocytes that kill virally infected and transformed cells and constitute a critical cellular subset of the innate immune system (Godfrey J, et al. Leuk Lymphoma 2012 53:1666-1676). Unlike cytotoxic CD8+ T lymphocytes, NK cells launch cytotoxicity without the requirement for prior sensitization, and can also eradicate MHC-l-negative cells (Nami-Mancinelli E, et al. Int Immunol 201123:427- 431).
- Innate lymphoid cells are tissue-resident innate lymphocytes that produce particular cytokines in response to infection, inflammation, and tissue injury.
- Type 1 innate lymphoid cells (ILC1s) produce interferon (IFN)-y.
- Type 2 innate lymphoid cells (ILC2s) express CRTH2, KLRG1, SST2, CD161 , and CD25, and produce amphiregulin, and type 2 cytokines (e.g., IL-4, IL-5, and IL-13).
- Type 3 innate lymphoid cells produce IL-22 as well as IL-17, IL-22, IFN- y, and GM-CSF, and can display NKp44, NKp30, and/or CD56 on the cell surface.
- CAR Chimeric antigen receptor
- TCR T cell receptor
- scFv single chain fragment of an antibody or other antibody fragment
- the non-MHC-restricted antigen recognition gives, e.g., T cells expressing CARs the ability to recognize an antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape.
- CARs when expressed in T cells, CARs advantageously do not dimerize with endogenous T-cell receptor (TCR) alpha and beta chains.
- CARs There are various formats of CARs, each of which contains different components.
- First generation CARs join an antibody-derived scFv to the CD3zeta ( ⁇ or z) intracellular signaling domain of the immune cell receptor through hinge and transmembrane domains.
- Secondary generation CARs incorporate an additional domain, e.g., CD28, 4-1 BB (41 BB), or ICOS, to supply a costimulatory signal.
- “Third generation” CARs contain two costimulatory domains fused with, e.g., the TCR CD3zeta chain.
- Third generation costimulatory domains may include, e.g., a combination of CD3zeta, CD27, CD28, 4-1 BB, ICOS, or 0X40.
- CARs in some embodiments, contain an ectodomain (e.g., CD3zeta), commonly derived from a single chain variable fragment (scFv), a hinge, a transmembrane domain, and an endodomain with one (first generation), two (second generation), or three (third generation) signaling domains derived from CD3 and/or co-stimulatory molecules (Maude et al., Blood. 2015; 125(26):4017-4023; Kakarla and Gottschalk, Cancer J. 2014; 20(2):151 -155).
- CD83-specific chimeric antigen receptors that can be expressed in immune effector cells to suppress alloreactive donor cells have been described in, e.g., U.S. Patent Publication Nos. 20210032336 and 20200108098, each of which is incorporated herein by reference in their entireties and in particular with respect to the description of CD83 chimeric antigen receptor-bearing immune cells.
- the chimeric antigen receptor comprises Fab or a single-chain variable fragment (scFv) of an antibody that specifically binds CD83 or a natural ligand of CD83.
- Examples of CAR polypeptides that bind CD83 include, but are not limited to, antibody-like constructs wherein the VH CDR1 sequence comprises the amino acid sequence GFSITTGGYWWT (SEQ ID NO:1), SDGIS (SEQ ID NO:7), or SNAMI (SEQ ID NO: 13); the VH CDR2 sequence comprises the amino acid sequence GYIFSSGNTNYNPSIKS (SEQ ID NO:2), IISSGGNTYYASWAKG (SEQ ID NO:8), or AMDSNSRTYYATWAKG (SEQ ID NO: 14); the VH CDR3 sequence comprises the amino acid sequence CARAYGKLGFDY (SEQ ID NO:3), WGGTYSI (SEQ ID NO:9), or GDGGSSDYTEM (SEQ ID NO: 15); the VL CDR1 sequence comprises the amino acid sequence TLSSQHSTYTIG (SEQ ID NO:4), QSSQSVYNNDFLS (SEQ ID NQ:10), or QSSQSV
- the CAR may contain the combinations of CDR sequences provided in Table 1.
- the CD83 binding portion of the CAR is an scFv.
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 19, VH-GBM00) QVQLKESGPGLVKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQKLEWMGYIFSSGNTN YNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTIVIVSS.
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 20, VL-GBMOO)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 21 , 20D04)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 22, 20D04)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 23, 11G05)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 24, 11G05)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 25, 14C12)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 26, 14C12)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 27, 020B08)
- EWQRGDVFTCSVMHEALHNHYTQKSIS RSPGK EWQRGDVFTCSVMHEALHNHYTQKSIS RSPGK.
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 28, 020B08)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 29, 006G05) METGLRWLLLVAVLKGVQCQSVEESGGRLVSPGTPLTLTCTASGFSLSSYDMSWVRQAPG KGLEYIGIISSSGSTYYASWAKGRFTISKTSTTVDLEVTSLTTEDTATYFCSREHAGYSGDTG HLWGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLT NGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPP ELLGGPSVGIGPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLRE QQFNSTIRVVSTL
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 30, 006G05) MDMRAPTQLLGLLLLWLPGARCAYDMTQTPASVEVAVGGTVAIKCQASQSVSSYLAWYQQ KPGQPPKPLIYEASMLAAGVSSRFKGSGSGTDFTLTISDLECDDAATYYCQQGYSISDIDNA FGGGTEVVVKGDPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGI ENSKTPQNSADCTYNLS STLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 31 , 96G08) METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLCTVSGIDLSSDGISWVRQAPGK
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 32, 96G08)
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 33, 95F04) METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLTCTVSGIDLSSNAMIWVRQAPRE GLEWIGAMDSNSRTYYATWAKGRFTISRTSSITVDLKITSPTTEDTATYFCARGDGGSSDYT EMWGPGTLVTVSSASTKGPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLS SGVHTFPAVLQSDLYILSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCIC TVPEVSSVFIFFPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREE
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 34, 95F04) MDTRAPTQLLGLLLLWLPGATFAQAVVTQTTSPVSAPVGGTVTINCQSSQSVYGNNELSW
- the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 35)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 36) LTQPPPASGTPGQQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYYGNDQRPSGVPD RFSASKSGTSASLAISGLQSEDEAHYYCAAWDGSLNGGVI FGGGTKVTLG.
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 37) VTQPPSASGTPGQRVTISCSGSSSNIGTNPVNWYQQLPGTAPKLLIYTTDQRPSGVPDRFS GSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGLYVFG TGTKVTVLG.
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 38)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 39)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 40)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 41)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 42)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 43)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 44)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 45)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 46)
- the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 47)
- the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 48, VH-GBM01) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 49, VH-GBM02) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQHPGKGLEWIGYIFSSGNTNY NPSIKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VH domain has been humanize and comprises the amino acid sequence: (SEQ ID NO: 50, VH-GBM03) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 51 , VH-GBM04) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 52, VH-GBM05) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTARYYCARAYG KLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 53, VH-GBM06) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAY GKLGFDYWGQGTLVTVSS.
- the anti-CD83 scFv VL domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 54, VL-GBM01) QLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYLMKVNSDGSHSKGD Gl PDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVF GSGTKVTVL.
- the anti-CD83 scFv VL domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 55, VL-GBM02) LPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIMKVNSDGSHSKGDGI PDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVF GSGTKVTVL.
- the heavy and light chains are optionally separated by a linker.
- Suitable linkers for scFv antibodies are known in the art.
- the linker comprises the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:56).
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 57) QPVLTQSPSASASLGNSVKITCTLSSQHSTYTIGWYQQHPDKAPKYVMYVNSDGSHSKGD GIPDRFSGSSSGAHRYLSISNIQPEDEADYFCGSSDSSGYVFGSGTQLTVLRAAASSGGGG
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 58) QVQLKESGPGLVKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQKLEWMGYIFSSGNTN YNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTLVTVSSG
- the anti-CD83 scFv comprises an amino acid sequence:
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 60) QVQLQESGPGINKPSQTLSLTCTVSGFSITTGGYWWTWIRQHPGKGLEWIGYIFSSGNTNY NPSIKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 61)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 62) QVQLQESGPGINKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 63)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 64)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 65)
- the anti-CD83 scFv comprises an amino acid sequence:
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 67) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 68)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 69)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 70)
- the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 71)
- CDR sequences and VH and VL sequences disclosed herein with respect to CARs also may be utilized in the context of an antibody, antigen-binding fragment thereof, or antibody-like construct, any of which may be conjugated to an additional moiety (e g., an antibody-drug conjugate).
- the CD83-targeted therapeutic of the present disclosure may be administered by any acceptable route, including parenteral and subcutaneous.
- Other routes include intravenous, intradermal, intramuscular, intraperitoneal, intranodal and intrasplenic, for example.
- the therapeutic is provided via systemic (e.g., intravenous) administration.
- a composition comprising the therapeutic typically is sterile.
- parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag, or vial having a stopper pierceable by a hypodermic injection needle, or a prefilled syringe.
- the method described herein further comprises administration of one or more other therapeutic agents.
- the method optionally comprises administering to the subject a second therapeutic agent selected from the group consisting of a corticosteroid, methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, everolimus, antithymocyte globulin, alemtuzumab, cyclophosphamide, ibrutinib, imatinib, infliximab, etanercept, tocilizumab, alemtuzumab, basiliximab, daclizumab, rituximab, denileukin diftitox, pentostatin, ruxolitinib, belumosudil, abatacept, cyclosporine, thalidomide, halofuginone, hydroxychloroquine, mesenchymal stem cells,
- a second therapeutic agent selected from the
- the disclosure further provides a method of identifying a subject at risk of developing acute GvHD, the method comprising measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD.
- a method of identifying a subject at risk of developing chronic GvHD comprising measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD.
- the method of identifying a subject at risk of developing chronic GvHD comprises measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
- the disclosure further provides a CD83-targeted therapeutic for use in a method of treating an alloimmune or autoimmune condition in a subject, wherein the method comprises measuring CD83 in a population of immune cells from the subject, and administering to the subject the CD83-targeted therapeutic.
- the disclosure further provides use of a CD83- targeted therapeutic for treating (or reducing the risk of developing or delaying the onset of) an alloimmune or autoimmune condition in a subject, wherein (a) CD83 expression is detected in at least 40% of CD4+ T cells in a population of immune cells from the subject or a CD83 gMFI of at least 740.5 is detected in the population of CD4+ T cells from the subject, (b) CD83 expression is detected in at least 19% of CD19+ B cells in a population of immune cells from the subject or a CD83 gMFI of at least 396 is detected in the population of CD19+ B cells from the subject, or (c) CD83 expression is detected in at least 25% of T helper follicular cells in the immune cell population from the subject or a CD83 gMFI of at least 469 is detected in the population of T helper follicular cells obtained from the subject.
- the subject has previously received allogeneic hematopoietic cell therapy.
- Example 1 - CD83 expression on CD4+ T cells is increased upon acute GvHD onset
- Acute GVHD remains a major cause of morbidity and death after allogeneic hematopoietic cell transplantation (alloHCT) for blood cancers and marrow failure syndromes.
- AlloHCT allogeneic hematopoietic cell transplantation
- Acute GVHD is typically diagnosed before day +100 and can affect recipient skin, gastrointestinal tract, and/or the liver.
- Current prevention strategies like calcineurin- inhibitors, broadly suppress pathogenic donor T cells that mediate GVHD, but also impair healthy effector T cells and regulatory T cells (Treg) that mediate beneficial graft-versus- leukemia (GVL) and immune tolerance, respectively.
- Reg regulatory T cells
- standard GVHD prevention offers incomplete protection at best and places alloHCT recipients at risk of disease relapse and opportunistic infections.
- peripheral blood ( ⁇ 50-80 mis) was serially drawn at day +21 and then weekly up to day +100, or at time of GVHD symptom onset.
- Peripheral blood mononuclear cells were purified by density gradient and stained for extracellular CD83 expression by flow cytometry.
- Results/Conclusion The results of the study are illustrated in Figures 1A-1 D, 2A- 2B, and 3A-3B.
- the data described herein establish that CD83 is expressed on alloreactive T cells at the time of acute GVHD onset. CD83 expression is negligible on Tregs, antileukemia T effectors, or effectors of viral immunity.
- Anti-CD83 chimeric antigen receptor (CAR) T cells that target CD83 can selectively eliminate pathogenic donor T cells that mediate acute GVHD.
- CAR chimeric antigen receptor
- CD83-targeted therapeutics e.g., CD83 CAR T cells
- CD83 CAR T cells CD83 CAR T cells
- CD83 expression on circulating, donor CD4+ T cells can be used to identify those with acute GVHD and potential risk of death from acute GVHD. Further, targeting CD83- expressing effectors of acute GVHD with CD83 CAR T or CD83-directed therapy offers a selective and effective means of preventing acute GVHD and maintaining graft-versus- leukemia as well as antiviral immunity after alloHCT.
- Example 2 CD83 expression on B cells and T helper follicular cells is increased upon chronic GVHD onset
- Chronic GVHD impacts over 60% of alloHCT recipients, effecting skin, muscle, joints, visceral organs, and the immune system.
- Chronic GVHD is a substantial source of post-transplant morbidity and death, and can emerge years after alloHCT.
- Chronic GVHD pathogenesis differs from acute GVHD, in that is consists of a triad of allo/autoantibody production, thymic dysfunction, and systemic fibrosis.
- chronic GVHD therapies are now FDA approved (e.g., ruxolitinib, ibrutinib, and belumosudil)
- many of these agents have nonselective, off-target toxicities that can cause cytopenias and/or infectious complications.
- the development of innovative, selective treatments for chronic GVHD is needed.
- peripheral blood ( ⁇ 50-80 mis) was serially drawn at day +60-100 and then weekly as clinically indicated, or at time of chronic GVHD symptom onset.
- Peripheral blood mononuclear cells were purified by density gradient and stained for extracellular CD83 expression by flow cytometry.
- a gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for circulating B cells and Tfh, respectively. This threshold can be used as a prognostic indicator for chronic GVHD as well as a cut off for therapeutic intervention with CD83 CAR T.
- CD83 is significantly expressed pathogenic, autoreactive B cells and T helper follicular cells (Tfh), but absent from healthy circulating B cells. This selectivity allows precise eradication of pathogenic effectors of chronic GVHD by using anti CD83 CAR T, yet spare cells needed for humoral and cellular immunity. This is a complete and needed departure from standard pharmacologic agents used to treat chronic GVHD.
- a gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for circulating B cells and Tfh, respectively. AlloHCT recipients with high CD83 expression on B cells of Tfh after day +100 had a significantly reduced overall survival. Thus, CD83 expression on chronic GVHD effectors offers a therapeutic and prognostic marker of disease, and can inform and guide clinical use of CD83 CAR T.
- CD83 expression on circulating, donor B cells and Tfh can be used to identify those with chronic GVHD and potential risk of death from chronic GVHD. Further, targeting CD83 expressing effectors of chronic GVHD with CD83 CAR T or CD83-directed therapy offers a selective and effective means of preventing chronic GVHD and maintaining graft- versus-leukemia as well as antiviral immunity after alloHCT.
- the data presented herein show CD83-directed therapy, like CD83 CAR T, avoids broad B cell aplasia as observed with CD19 CAR T.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.
Description
CD83 AND ALLO- AND AUTOIMMUNE CONDITIONS
Cross-Reference to Related Applications
[0001] This application claims priority to U.S. Provisional Patent Application No. 63/292,858, filed December 22, 2021 , the disclosure of which is hereby incorporated by reference in its entirety.
Field
[0002] The application relates generally to materials and methods for identifying and/or treating subjects at risk of suffering from an allo- or autoimmune condition, such as Graft versus Host Disease (GvHD).
Incorporation by Reference of Material Submitted Electronically
[0003] A Sequence Listing, which is a part of the present disclosure, is submitted concurrently with the specification as a text file. The name of the text file containing the Sequence Listing is “57191_Seqlisting.XML." The Sequence Listing was created on November 7, 2022, and is 4,037,579 bytes in size. The subject matter of the Sequence Listing is incorporated by reference herein in its entirety.
Background
[0004] Autoimmunity is an immune response to self-antigens, which results in the body attacking normal cells and tissues. There are more than 80 types of autoimmune diseases that present unique clinical symptoms and affect different parts of the body. In contrast, alloimmunity is an immune response to antigens from different members of the same species. Alloimmunity is triggered primarily by differences in the major histocompatibility complex between individuals within a species. The body’s response to alloimmune conditions and autoimmune conditions mimics the response against infection, involving activation of immune cells, inflammation, and tissue damage.
[0005] Host-anti-graft immune response remains a significant challenge in transplantation settings. Graft versus Host Disease (GvHD) occurs when donor immune cells transferred to an allogeneic recipient attack tissues in the recipient. The skin, liver, and intestinal tract are often affected, resulting in significant damage and morbidity. GvHD is a common complication of allogeneic hematopoietic cell transplantation (HCT), but also may develop after solid organ transplantation. It has been estimated that acute GvHD develops in 35- 50% of patients given H LA-identical bone marrow grafts within the first 100 days of transplantation, and chronic GvHD affects about 45% of all long-term survivors. Deeg & Storb, Annu Rev Med. 1984; 35:11-24.
[0006] Currently, GvHD is typically treated with immunosuppressive and cytotoxic drugs. A challenge in the field is that most patients are treated prophylactically to inhibit or prevent the onset of GvHD, resulting in many patients being subjected to immune suppressing therapies or cytotoxic therapies unnecessarily or for a longer period of time than needed. There is a need in the art of improved materials and methods for identifying subjects at risk of suffering from allo- or autoimmune conditions prior to the onset of symptoms.
Summary
[0007] The disclosure provides a method of treating or reducing the risk of developing an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic. In one aspect, the autoimmune condition is acute graft-versus- host disease (GvHD) and the population of immune cells in step (a) comprises CD4+ T cells. Optionally, the method is performed within 30 days of the subject receiving allogeneic hematopoietic cell transplantation and, in various aspects, prior to the onset of acute GvHD symptoms. Alternatively, the condition is chronic GvHD and the population of immune cells in step (a) comprises CD19+ B cells and/or T helper follicular cells. In this respect, the method is optionally performed after 60 days of the subject receiving allogeneic hematopoietic cell transplantation and, in various aspects, prior to the onset of chronic GvHD symptoms.
[0008] The disclosure further provides a method of identifying a subject at risk of developing acute GvHD. The method comprises measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD.
[0009] The disclosure also provides a method of identifying a subject at risk of developing chronic GvHD. The method comprises measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD. Alternatively (or in addition), the method comprises measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
Brief Description of the Drawings
[0010] Figures 1A-1 D: CD83 expression on CD4+ T cells is increased upon acute GvHD onset. CD83 expression was evaluated among patients post allogeneic hematopoietic cell
transplantation without or with grade ll-IV (n=24) acute GVHD (time-matched controls). Figures 1A-1 D are bar graphs and ROC (receiver operating characteristic curve) depicting %CD83 expression and geometric mean fluorescence intensity are shown. ***0.0001, ****P<0.000 , and AUC = area under the curve. Figure 1 A is a bar graph illustrating %CD83+ CD4+ T cells in subjects not suffering from acute GvHD and subjects suffering from Grade ll-IV acute GvHD. Figure 1C is a bar graph illustrating CD83 gMFI (geometric mean fluorescence intensity) by CD4+ T cells in subjects not suffering from acute GvHD and subjects suffering from Grade ll-IV acute GvHD. Figures 1 B and 1 D are a line graphs illustrating % sensitivity.
[0011] Figures 2A-2B: Earlier acute GvHD diagnosis is associated with increased CD4+ T cell CD83 expression. The figures are line graphs showing the association (Spearman r) between CD4+ T cell CD83 expression and timing of acute GVHD onset using (Figure 1A) %CD83 expression and (Figure 1 B) gMFI. n= 24 grade ll-IV acute GVHD patients.
[0012] Figures 3A-3B: Increased CD4+ T cell CD83 expression by day +100 is associated with reduced survival after alloHCT. Figure 3A is a line graph showing the overall survival of alloHCT recipients (n=40) based on CD4+ T cell CD83 expression. CD83 expression was determined at time of acute GVHD diagnosis (n=20) or sampled among time-matched controls (n=20). A gMFI cutoff of 740.5 was used to determine low versus high CD83 expression. Top line - low CD83 gMFI expression; bottom line - high CD83 gMFI expression. Figure 3B is a line graph showing the overall survival of the alloHCT recipients based on diagnosis of grade ll-IV acute GVHD by day +100. Top line - no GvHD; bottom line - Grade ll-IV.
[0013] Figures 4A-4H: CD83 expression on B cells and T helper follicular cells is increased upon chronic GVHD onset. CD83 expression was evaluated among patients post allogeneic hematopoietic cell transplantation without (n=24) or with chronic GVHD (n=24) (time-matched controls). Figures 4A and 4D illustrate %CD83+ cells (Figure 4A) and CD83 gMFI (geometric mean fluorescence intensity; Figure 4D) on B cells, T helper follicular cells (Tfh) and monocytes. Figures 4B, 4C, 4E, and 4F are ROC curves depicting %CD83 expression and geometric mean fluorescence intensity. Tfh were identified as CD4+, CD45RAneg, CXCR5+ T cells. **P=0.01 -0.001 , ****P<0.0001 , NS = not significant, and AUC = area under the curve. Figures 4G-4H shows the (Figure 4G) %CD83+ and (Figure 4H) CD83 gMFI among age-associated (ABC) (CD19+, CD2T, CD11c+), IgD* memory (CD19+, IgD*, CD38|0, CD27+), pregerminal (CD19+, IgD*, CD38+, CD27+), transitional (CD19+, IgD*, CD38+, CD27 ), plasmablast (CD19+, IgD10, CD38hi, CD27+), and postgerminal memory (CD19+, IgD10, CD3810, CD27+) B cell subsets from a group of patients with chronic GVHD
(n=9). *P<0.05, **P=0.01-0.001, ****P<0.0001 , NS= not significant, and AUG = area under the curve.
[0014] Figures 5A-5C: Increased B cell or Tfh CD83 expression after day +100 is associated with reduced survival after alloHCT. The graphs show the overall survival of (95% Cl) alloHCT recipients (n=37) based on (Figure 5A) B cell or (Figure 5B) T helper follicular (Tfh) cell CD83 expression. CD83 expression was determined at time of chronic GVHD diagnosis (n=17) or sampled among time-matched controls (n=20). A gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for B cells and Tfh, respectively. Figure 5C is a graph showing overall survival based on the diagnosis of chronic GVHD after day +100.
[0015] Figures 6A-6C: Auto-activated B cells from patients with chronic GvHD were stimulated with antihuman IgM and OP9-DL1 cells and cultured with anti-CD19 CAR T cells, anti-CD83 CAR T cells, or untransduced T cells for 72 hours. The graphs show the absolute number of (Figure 6A) CD83+ B cells and (Figure 6B) the total number of B cells recovered after the 72-hour co-culture. n=4 independent experiments. *P<0.05, **P=0.01-0.001 , ***p=0 001-0.0001, and NS= not significant. The CD83 CAR T cells eliminated the autoreactive CD83 positive B cells, but did not cause complete B cell aplasia observed with CD19 CAR T cell therapy. The data show that patients at risk of chronic GvHD (i.e., identified using the methods described herein) may be treated with CD83 CAR T cells, while preserving B cell function to fight infections. This is a significant advantage to CD19 CAR T cell treatment, which can cause life-long B cell aplasia and, by extension, life-long risk for opportunistic infections and need for IV-lg replacement therapy, which is only partially protective against opportunistic infections.
Detailed Description
[0016] The disclosure is based, at least in part, on the surprising discovery that CD83 expression in various immune cells is an indicator of the onset of allo- or autoimmunity, thereby allowing a means for identifying subjects at risk of developing an alloimmune condition or autoimmune condition or identifying subjects in the very early stages of an allo- or autoimmune condition. The materials and methods described herein allow for more informed decisions as to whether and when to treat subjects with therapeutics effective against alloimmune and/or autoimmune conditions.
[0017] In particular, the data presented herein demonstrate that CD83+ CD4+ T cells are increased among alloHCT recipients with grade ll-IV acute GVHD. CD83 expression is exceedingly low on regulatory T cells or CD8+ T cells, which are critical for durable immune tolerance and beneficial graft-versus-leukemia. The data presented herein demonstrate that
the frequency of peripheral CD83+ CD4+ T cells and the intensity of CD83 expression are significantly increased among patients with grade ll-IV acute GvHD, and this correlates with disease onset. The materials and methods of the disclosure can inform the timing of intervention therapies (e g., CD83 CAR T administration or other anti-CD83 targeted therapy) to prevent or treat acute GvHD. A significant survival advantage also was identified for those with low CD83 expression on circulating CD4+ T cells after alloHCT.
[0018] The disclosure also is based, at least in part, on the discovery that CD83 expression on B cells and T helper follicular cells is increased upon chronic GvHD onset. Autoreactive B cells and T helper follicular (Tfh) cells (a subset of CD4+ helper T cells) contribute to chronic GVHD pathogenesis. The frequency of CD83+ B cells and Tfh, but not monocytes, were significantly increased among patients with chronic GVHD. Further, CD83 expression on B cells and Tfh significantly correlated with chronic GVHD onset. Additionally, low CD83 expression on either B cells or Tfh was determined to be associated with a significant survival advantage after alloHCT. Thus, CD83 expression on B cell and Tfh cells, implicated in chronic GvHD, can serve as a biomarker for disease.
[0019] The disclosure provides a method of treating or reducing the risk of developing an alloimmune or autoimmune condition in a subject in need thereof. The method comprises measuring CD83 in a population of immune cells from the subject and administering to the subject a CD83-targeted therapeutic.
[0020] In various aspects, the condition is GvHD. The GvHD may be acute GvHD or may be chronic GvHD. While the symptoms of acute and chronic GvHD overlap, acute and chronic GvHD are immunologically distinct complications (e.g., complications of alloHCT). Acute GvHD is primarily mediated by alloreactive T cells. Acute GvHD is potentiated by early tissue damage during the conditioning regimens (e.g., radiation and/or chemotherapy) used to prepare patients to receive allogeneic hematopoietic cells. Further, disruption of the host gut microbiota further fuels alloreactivity by the lack of intestinal butyrate. Acute GvHD typically impacts the skin, gut, and liver and often occurs before day 100 post-transplant. Current strategies used to prevent acute GvHD primarily rely upon broad inhibition of donor T cell function, which often fails to mediate immune tolerance, impairs graft-versus leukemia, and can increase the risk for opportunistic infections. The data provided herein allows use of CD83 expression on alloreactive donor CD4+ T cells to determine those at highest risk of acute GvHD and eliminate that risk with CD83-targeted therapy.
[0021] Chronic GvHD stems from a unique triad of thymic impairment, auto- and alloantibody production by reactive B cells, and systemic tissue fibrosis. Chronic GvHD is a systemic disease affecting host mucocutaneous tissues, musculoskeletal system,
gastrointestinal tract, liver, lungs, immune system, and cardiovascular system. Chronic GvHD typically occurs later after transplantation (e.g., after day 100 post alloHCT), and can essentially develop at any time, even decades after the procedure. Similar to acute GvHD, treatment of chronic GvHD requires the use of broadly immune suppressive medications. The ability to track chronic GvHD risk by the expression of CD83 on B cells and Tfh has robust clinical impact.
[0022] In various aspects of the disclosure, the measuring step is performed prior to the onset of GvHD symptoms (i.e. , the subject is not suffering from one or more symptoms of GvHD or other allo- or autoimmune condition). Common symptoms of acute GvHD have been reported in the literature and include, but are not limited to, skin rash or reddening, discoloration of the skin and/or eyes (Jaundice), nausea, vomiting, diarrhea, and abdominal cramping. Similarly, common symptoms of chronic GvHD have been reported in the literature and include, but are not limited to, skin rash or discoloration, tightness or thickening of the skin, discoloration of the eyes, vision changes, dry mouth or oral ulcers, difficulty swallowing, weight loss, abdominal swelling, shortness of breath, fatigue, muscle weakness or pain, sensitivity or tightness in the joints, cytopenia, or pericarditis. GvHD is monitored using a number of techniques, including (but not limited to) clinical examination, X-ray, CT scan, liver function tests, PET scan, MRI, capsule endoscopy, and biopsy.
[0023] The method of the disclosure comprises measuring CD83 in a population of immune cells. Any suitable immune cell type may be utilized, including, e.g., CD4+ T cells, CD19+ B cells, and/or T helper follicular cells. Methods of identifying particular immune cell types are known in the art and include fluorescence-activated cell sorting (FACS).
[0024] CD83 may be measured in a variety of ways. In various aspects, the method comprises measuring CD83 protein levels. Methods of determining protein levels or identifying expression of proteins in a target cell type are known in the art. Optionally, CD83 protein levels are determined via western blot or dot blot analysis, immunohistochemistry (IHC, e.g., quantitative immunohistochemistry), flow cytometry, immunocytochemistry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunosorbent spot (ELISPOT; Coligan, J. E., et al., eds. (1995) Current Protocols in Immunology. Wiley, New York), radioimmunoassay, or chemiluminescent immunoassay. CD83 protein levels also may be measured via geometric mean fluorescence intensity (gM Fl). CD83 may be quantified and monitored in real-time on cells of interest (e.g., CD4+ T cells, Tfh, or B cells) by, for example, peripheral blood draws and measured by flow cytometry. Flow cytometry is a feasible method of tracking various cell markers of GVHD, such as phosphorylated STAT3, as early as 21 days after allogeneic hematopoietic cell transplantation. See, e.g., Pidala, J., et al., (2021) Clinical Cancer Research. 27(10):2712-2722.
[0025] Alternatively or in addition, measuring CD83 in a population of immune cells from the subject comprises measuring CD83 RNA levels. In this regard, CD83 RNA is optionally measured via real time polymerase chain reaction (qRT-PCR) or RNA sequencing. The sequence of CD83 is known in the art. See, e g., Genbank Accession Nos. NM_001040280 and NM_004233.
[0026] CD83 protein levels may be expressed as a quantity or concentration of CD83 found in an immune cell population, or it may be expressed as a percentage of immune cells expressing CD83.
[0027] In various aspects of the disclosure, the condition is acute GvHD, and the population of immune cells comprises CD4+ T cells. In this regard, the measuring step optionally comprises detecting CD83 expression in at least 40% of CD4+ T cells in the population (e.g., at least 45%, at least 55%, or at least 60% of the cells in the population). The methodology may include (but does not require) flow cytometry, staining for live/dead cells (optionally including dump gate for CD19, CD16, CD14, etc.), CD3+, CD4+, and CD83+. As demonstrated by the data provided herein, CD83 expression in at least 40% of CD4+ T cells in a subject (e.g., a subject administered allogeneic hematopoietic cell transplantation) is associated with progression to Grade ll-IV acute GvHD. Alternatively or in addition, the measuring step comprises measuring CD83 using Geometric mean fluorescence intensity (gM Fl) and detecting a gMFI of at least 740.5. Also, optionally, the method is performed within 30 days (e.g., within 25 days, within 20 days, within 15 days, within 10 days, or within 5 days) of the subject receiving a transplant, such as an allogeneic hematopoietic cell transplant.
[0028] In alternative aspects of the disclosure, the condition is chronic GvHD and the population of immune cells comprises CD19+ B cells and/or T helper follicular cells. For example, the disclosure contemplates a method comprising detecting CD83 expression in at least 19% of CD19+ B cells in the population (e.g., at least 20%, at least 25%, or at least 30% of CD19+ B cells) and/or measuring CD19+ B cell CD83 using gMFI and detecting a gMFI of at least 396. The disclosure also provides a method comprising detecting CD83 expression in at least 25% of T helper follicular cells (e.g., a least 30%, at least 35%, or at least 40%) in the population and/or measuring T helper follicular cell CD83 using gMFI and detecting a gMFI of at least 469. Optionally, the method is performed after 60 days (e.g., after 75 days, after 90 days, or after 120 days) of the subject receiving a transplant (e.g., an allogeneic hematopoietic cell transplant). Optionally the method is performed prior to the onset of chronic GvHD symptoms.
[0029] While the disclosure above references GvHD, the method of the disclosure is suitable for use in the context of other autoimmune or alloimmune conditions. In various aspects, the condition is systemic lupus erythematosus (SLE), multiple sclerosis, sjogren’s syndrome, systemic sclerosis/scleroderma, inflammatory bowel disease, or rheumatoid arthritis.
[0030] The term "treat," as well as words related thereto, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the methods of treating a condition or disease of the present disclosure can provide any amount or any level of treatment. Furthermore, the treatment provided by the method may include treatment of one or more conditions or symptoms or signs of the disease being treated. For instance, the treatment method of the present disclosure may inhibit one or more symptoms of the disease. Also, the treatment provided by the methods of the present disclosure may encompass slowing the progression of the disease. The term "treat" also encompasses prophylactic treatment of the disease. Accordingly, the treatment provided by the presently disclosed method may delay the onset or reoccurrence/relapse of the disease being prophylactically treated. In exemplary aspects, the method delays the onset of the condition by 1 day, 2 days, 4 days, 6 days, 8 days, 10 days, 15 days, 30 days, two months, 4 months, 6 months, 1 year, 2 years, 4 years, or more. The prophylactic treatment encompasses reducing the risk of the condition being treated. In exemplary aspects, the method reduces the risk of the condition 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or more. Thus, the term “therapeutically effective” refers to a sufficient quantity of a composition which ameliorates one or more causes or symptoms of a condition or disease.
[0031] In certain aspects, the method of treating the disease may be regarded as a method of inhibiting the disease or a symptom thereof. As used herein, the term "inhibit" and words stemming therefrom may not be a 100% or complete inhibition or abrogation. Rather, there are varying degrees of inhibition of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. The presently disclosed methods may inhibit the onset or re-occurrence of the condition or a symptom thereof to any amount or level. In exemplary embodiments, the inhibition provided by the methods is at least or about a 10% inhibition (e.g., at least or about a 20% inhibition, at least or about a 30% inhibition, at least or about a 40% inhibition, at least or about a 50% inhibition, at least or about a 60% inhibition, at least or about a 70% inhibition, at least or about a 80% inhibition, at least or about a 90% inhibition, at least or about a 95% inhibition, at least or about a 98% inhibition).
[0032] The subject is a mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals from the order Carnivora, including Felines (cats) and Canines (dogs), mammals from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). In some aspects, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). Preferably, the mammal is a human.
[0033] In various aspects of the disclosure, the method comprises administering to the subject a CD83-targeted therapeutic. A “CD83-targeted therapeutic” is a biological agent which provides a beneficial biological response with respect to treating or inhibiting the alloimmune or autoimmune condition and which specifically binds CD83 on the immune cell surface. An agent "specifically binds" to a target if it reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular target (e g., CD83) than it does with alternative targets (e.g., other cell surface proteins). For example, a CD83-targeted therapeutic that specifically binds CD83 is one that binds CD83 with greater affinity, avidity, more readily, and/or with greater duration than it binds to other non-CD83 proteins. It is also understood that, for example, a CD83-targeted therapeutic which specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, "specific binding" does not necessarily require (although it can include) exclusive binding. In general, under designated assay conditions, a CD83- targeted therapeutic binds preferentially to a particular target molecule and does not bind in a significant amount to other components present in a test sample.
[0034] A variety of assay formats may be used to select or characterize a CD83-targeted therapeutic. For example, solid-phase ELISA immunoassay, immunoprecipitation, BIAcore™ (GE Healthcare, Piscataway, NJ), fluorescence-activated cell sorting (FACS), Octet™ (ForteBio, Inc., Menlo Park, CA) and Western blot analysis are among many assays that may be used to characterize binding to CD83. Typically, a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 times background. Even more specifically, a CD83-targeted therapeutic is said to "specifically bind" CD83 when the equilibrium dissociation constant (KD) value is < 1 pM, such as < 100 nM, < 10 nM, < 100 pM, < 10 pM, or < 1 pM.
[0035] In various aspects, the CD83-targeted therapeutic is an antibody that binds CD83, an antigen-binding antibody fragment that binds CD83 (e.g., an antigen binding portion of an antibody), or an antibody-like construct that binds CD83. The term "antibody" refers to an intact antigen-binding immunoglobulin. The antibody can be an IgA, IgD, IgE, IgG, or IgM antibody, including any one of lgG1 , lgG2, lgG3, or lgG4. In various embodiments, an intact
antibody comprises two full-length heavy chains and two full-length light chains. An antibody has a variable region and a constant region. In IgG formats, a variable region is generally about 100-110 or more amino acids, comprises three complementarity determining regions (CDRs), is primarily responsible for antigen recognition, and substantially varies among other antibodies that bind to different antigens. CDR sequences are described further below. A variable region typically comprises at least three heavy or light chain CDRs (Kabat et al., 1991 , Sequences of Proteins of Immunological Interest, Public Health Service N.I.H., Bethesda, Md.; see also Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342: 877-883), within a framework region (designated framework regions 1-4, FR1, FR2, FR3, and FR4, by Kabat et al., 1991; see also Chothia and Lesk, 1987, supra). The constant region allows the antibody to recruit cells and molecules of the immune system.
[0036] The architecture of antibodies has been exploited to create a growing range of alternative formats that span a molecular-weight range of at least about 12-150 kDa and have a valency (n) range from monomeric, to dimeric, to trimeric, to tetrameric, and potentially higher; such alternative formats are referred to herein as “antibody-like constructs.” Antibody-like constructs include those based on the full antibody structure and those that mimic antibody fragments which retain full antigen-binding capacity, e.g., scFvs, Fabs and VHH. The smallest antigen-binding fragment that retains its complete antigen binding site is the Fv fragment, which consists entirely of variable (V) regions. A soluble, flexible amino acid peptide linker is used to connect the V regions to a scFv (single chain fragment variable) fragment for stabilization of the molecule, or the constant (C) domains are added to the V regions to generate a Fab fragment (fragment, antigen-binding). Other antibody protein products include disulfide-bond stabilized scFv (ds-scFv), single chain Fab (scFab), as well as di- and multimeric antibody formats like dia-, tria- and tetra-bodies, or minibodies (miniAbs) that comprise different formats consisting of scFvs linked to oligomerization domains. The smallest fragments are VHH/VH of camelid heavy chain Abs as well as single domain Abs (sdAb). The building block that is most frequently used to create different antibody formats is the single-chain variable (V)-domain antibody fragment (scFv), which comprises V domains from the heavy and light chain (VH and VL domain) linked by a peptide linker of ~15 amino acid residues. A peptibody or peptide-Fc fusion is yet another antibody-like construct protein product. The structure of a peptibody consists of a biologically active peptide grafted onto an Fc domain. Peptibodies are described in the art. See, e.g., Shimamoto et al., mAbs 4(5): 586-591 (2012).
[0037] Other antibody protein products include a single chain antibody (SCA), a diabody, a triabody, a tetrabody, bispecific or trispecific antibodies, and the like. Bispecific antibodies
can be divided into five major classes: BsIgG, appended IgG, BsAb fragments (e.g., bispecific single chain antibodies), bispecific fusion proteins (e.g., antigen binding domains fused to an effector moiety), and BsAb conjugates. See, e.g., Spiess et al., Molecular Immunology 67(2) Part A: 97-106 (2015). Examples of bispecific antibody constructs also include, but are not limited to, tandem scFvs, bispecific T cell engager (BiTE®) format (a fusion protein consisting of two single-chain variable fragments (scFvs) joined by a linker), and Fab2 bispecifics. See, e.g., Chames & Baty, 2009, mAbs 1 [6]: 1-9; and Holliger & Hudson, 2005, Nature Biotechnology 23[9]: 1126-1136; Wu et al., 2007, Nature Biotechnology 25[11]: 1290-1297; Michaelson et al., 2009, mAbs 1[2]:128-141 ; International Patent Publication Nos. WO 2009032782 and WO 2006020258; Zuo et al., 2000, Protein Engineering 13[5]:361-367; U.S. Patent Application Publication No. 20020103345; Shen et al., 2006, J Biol Chem 281[16]: 10706-10714; Lu et al., 2005, J Biol Chem 280[20j: 19665- 19672; and Kontermann, 2012 MAbs 4(2): 182, all of which are expressly incorporated herein. Multispecific antibody constructs, such as trispecific antibody constructs (including three binding domains) or constructs having more than three (e.g. four, five, or more) specificities, also are contemplated.
[0038] The antibodies (or antigen-binding fragments thereof or antibody-like construct) may be a human antibody (i.e., having one or more variable and constant regions derived from human immunoglobulin sequences), humanized (i.e., have a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject), or chimeric (i.e., containing one or more regions from one antibody and one or more regions from one or more other antibodies).
[0039] In various aspects of the disclosure, the CD83-targeted therapeutic is a nanobody, i.e., an antibody-like construct based on heavy-chain only antibodies (HcAbs) in camelids. HcAbs consist of just two heavy chains with a single variable domain (VHH). In various aspects, the nanobody of the disclosure comprises a VHH domain and one or two constant domains (e.g., CH2 and CH3).
[0040] In some aspects, the antibody, antigen-binding fragment, or antibody-like construct is linked (or conjugated) to one or more moieties. For example, the conjugate moiety may comprise a therapeutic agent, a radioactive isotope, a detectable label, a pharmacokinetic modifying moiety (e.g., human serum albumin), or a purifying moiety (e.g., tag). The conjugate moiety may be covalently attached either directly to the therapeutic or via a linker.
[0041] In various aspects, the CD83-targeted therapeutic is an immune effector cell genetically modified to express a chimeric antigen receptor (CAR) polypeptide that selectively binds CD83. These cells are preferably obtained from the subject to be treated (i.e., are autologous). However, in some embodiments, immune effector cell lines or donor effector cells (allogeneic) are used. Immune effector cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Immune effector cells can be obtained from blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll™ separation. For example, cells from the circulating blood of an individual may be obtained by apheresis. In some embodiments, immune effector cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL™ gradient or by counterflow centrifugal elutriation. A specific subpopulation of immune effector cells can be further isolated by positive or negative selection techniques. For example, immune effector cells can be isolated using a combination of antibodies directed to surface markers unique to the positively selected cells, e.g., by incubation with antibody-conjugated beads for a time period sufficient for positive selection of the desired immune effector cells. Alternatively, enrichment of immune effector cells population can be accomplished by negative selection using a combination of antibodies directed to surface markers unique to the negatively selected cells.
[0042] The immune effector cells may comprise any leukocyte involved in defending the body against infectious disease and foreign materials. For example, the immune effector cells can comprise lymphocytes, monocytes, macrophages, dendritic cells, mast cells, neutrophils, basophils, eosinophils, or any combinations thereof. Indeed, examples of suitable immune effector cells include, but are not limited to Natural Killer (NK) cells, cytotoxic T cells, regulatory T cells, and innate lymphoid cells (types 1-3).
[0043] T cells or T lymphocytes can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surface. Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response.
These cells can differentiate into one of several subtypes, including TH1 , TH2, TH3, TH7, TH9, or TFH, which secrete different cytokines to facilitate a different type of immune response.
[0044] Cytotoxic T cells (Tc cells or CTLs) destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T cells since they express the CDS glycoprotein at their surface. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells.
[0045] Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon reexposure to their cognate antigen, thus providing the immune system with "memory" against past infections. Memory cells may be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO.
[0046] Regulatory T cells (Treg cells), formerly known as suppressor T cells, dampen T cell-mediated immunity toward the end of an immune reaction and to suppress auto-reactive T cells that escaped the process of negative selection in the thymus. Two major classes of CD4+ Treg cells have been described-naturally occurring Treg cells and adaptive Treg cells.
[0047] Natural killer T (NKT) cells (not to be confused with natural killer (NK) cells) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells that recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen presented by a molecule called CD1d.
[0048] The T cells may comprise a mixture of CD4+ cells. In other embodiments, the T cells are enriched for one or more subsets based on cell surface expression. In some instances, the T cells are cytotoxic CD8+ T lymphocytes. In some embodiments, the T cells comprise gamma-delta T cells, which possess a distinct T-cell receptor (TCR) having one gamma chain and one delta chain instead of alpha and beta chains.
[0049] Natural-killer (NK) cells are CD56+CD3- large granular lymphocytes that kill virally infected and transformed cells and constitute a critical cellular subset of the innate immune system (Godfrey J, et al. Leuk Lymphoma 2012 53:1666-1676). Unlike cytotoxic CD8+ T lymphocytes, NK cells launch cytotoxicity without the requirement for prior sensitization, and can also eradicate MHC-l-negative cells (Nami-Mancinelli E, et al. Int Immunol 201123:427- 431).
[0050] Innate lymphoid cells are tissue-resident innate lymphocytes that produce particular cytokines in response to infection, inflammation, and tissue injury. Type 1 innate
lymphoid cells (ILC1s) produce interferon (IFN)-y. Type 2 innate lymphoid cells (ILC2s) express CRTH2, KLRG1, SST2, CD161 , and CD25, and produce amphiregulin, and type 2 cytokines (e.g., IL-4, IL-5, and IL-13). Type 3 innate lymphoid cells (ILC3s) produce IL-22 as well as IL-17, IL-22, IFN- y, and GM-CSF, and can display NKp44, NKp30, and/or CD56 on the cell surface.
[0051] "Chimeric antigen receptor" or "CAR" refers to an artificial immune cell receptor that is engineered to recognize and bind to an antigen expressed by a target cell, such as a tumor cell. Generally, a CAR is designed for a T cell and is a chimera of a signaling domain of the T cell receptor (TCR) complex and an antigen-recognizing domain (e.g., a single chain fragment (scFv) of an antibody or other antibody fragment) (Enblad et al., Human Gene Therapy. 2015; 26(8) :498- 505). CARs have the ability to redirect immune cell specificity and reactivity toward a selected target in a non-MHC-restricted manner. The non-MHC-restricted antigen recognition gives, e.g., T cells expressing CARs the ability to recognize an antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape. Moreover, when expressed in T cells, CARs advantageously do not dimerize with endogenous T-cell receptor (TCR) alpha and beta chains.
[0052] There are various formats of CARs, each of which contains different components. "First generation" CARs join an antibody-derived scFv to the CD3zeta (^ or z) intracellular signaling domain of the immune cell receptor through hinge and transmembrane domains. "Second generation" CARs incorporate an additional domain, e.g., CD28, 4-1 BB (41 BB), or ICOS, to supply a costimulatory signal. "Third generation" CARs contain two costimulatory domains fused with, e.g., the TCR CD3zeta chain. Third generation costimulatory domains may include, e.g., a combination of CD3zeta, CD27, CD28, 4-1 BB, ICOS, or 0X40. CARs, in some embodiments, contain an ectodomain (e.g., CD3zeta), commonly derived from a single chain variable fragment (scFv), a hinge, a transmembrane domain, and an endodomain with one (first generation), two (second generation), or three (third generation) signaling domains derived from CD3 and/or co-stimulatory molecules (Maude et al., Blood. 2015; 125(26):4017-4023; Kakarla and Gottschalk, Cancer J. 2014; 20(2):151 -155).
[0053] CD83-specific chimeric antigen receptors (CAR) that can be expressed in immune effector cells to suppress alloreactive donor cells have been described in, e.g., U.S. Patent Publication Nos. 20210032336 and 20200108098, each of which is incorporated herein by reference in their entireties and in particular with respect to the description of CD83 chimeric antigen receptor-bearing immune cells. In various aspects of the disclosure, the chimeric antigen receptor comprises Fab or a single-chain variable fragment (scFv) of an antibody that specifically binds CD83 or a natural ligand of CD83.
[0054] Examples of CAR polypeptides that bind CD83 include, but are not limited to, antibody-like constructs wherein the VH CDR1 sequence comprises the amino acid sequence GFSITTGGYWWT (SEQ ID NO:1), SDGIS (SEQ ID NO:7), or SNAMI (SEQ ID NO: 13); the VH CDR2 sequence comprises the amino acid sequence GYIFSSGNTNYNPSIKS (SEQ ID NO:2), IISSGGNTYYASWAKG (SEQ ID NO:8), or AMDSNSRTYYATWAKG (SEQ ID NO: 14); the VH CDR3 sequence comprises the amino acid sequence CARAYGKLGFDY (SEQ ID NO:3), WGGTYSI (SEQ ID NO:9), or GDGGSSDYTEM (SEQ ID NO: 15); the VL CDR1 sequence comprises the amino acid sequence TLSSQHSTYTIG (SEQ ID NO:4), QSSQSVYNNDFLS (SEQ ID NQ:10), or QSSQSVYGNNELS (SEQ ID NO: 16); the VL CDR2 sequence comprises the amino acid sequence VNSDGSHSKGD (SEQ ID NO:5), YASTLAS (SEQ ID NO:11), or QASSLAS (SEQ ID NO: 17); and the VL CDR3 sequence comprises the amino acid sequence GSSDSSGYV (SEQ ID NO:6), TGTYGNSAWYEDA (SEQ ID NO:12), or LGEYSISADNH (SEQ ID NO:18).
[0056] In various aspects of the disclosure, the CD83 binding portion of the CAR is an scFv.
[0057] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 19, VH-GBM00)
QVQLKESGPGLVKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQKLEWMGYIFSSGNTN YNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTIVIVSS.
[0058] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 20, VL-GBMOO)
QPVLTQSPSASASLGNSVKITCTISSQHSTYTIGWYQQHPDKAPKYVMYVNSDGSHSKGD
GIPDRFSGSSSGAHRYLSIS NIQPEDEADYFCGSSDSSGYVFGSGTQLTVL
[0059] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 21 , 20D04)
METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLTCTVSGFSLSNNAINWVRQAPG
KGLEWIGYIWSGGLTYYANW AEGRFTISKTSTTVDLKMTSPTIEDTATYFCARGINNSAL
WGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNG
VRTFPSVRQSSGLYSLSSVV SVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPPE
LLGGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLREQ
QFNSTIRWSTLPIAHQDWL RGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPP
REELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYNKLSVPTS
EWQRGDVFTCSVMHEALHN HYTQKSISRSPGK.
[0060] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 22, 20D04)
MDMRAPTQLLGLLLLWLPGARCADVVMTQTPASVSAAVGGTVTINCQASESISNYLSWYQ
QKPGQPPKLLIYRTSTUKSG VSSRFKGSGSGTEYTLTISGVQCDDVATYYCQCTSGGKFI
SDGAAFGGGTEWVKGDPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTT
QTTGIENSKTPQNSADCTYN LSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
[0061] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 23, 11G05)
METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLTCTVSGFTISDYDLSWVRQAPG
EGLKYIGFIAIDGNPYYATW AKGRFTISKTSTTVDLKITAPTTEDTATYFCARGAGDLWG
PGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGVRT
FPSVRQSSGLYSLSSVVSV TSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPPELL
GGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLREQQF
NSTIRVVSTLPIAHQDWLR GKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPPR
EELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYNKLSVPTSE
WQRGDVFTCSVMHEALHNH YTQKSISRSPGK.
[0062] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 24, 11G05)
MDTREPTQLLGLLLLWLPGARCADVVMTQTPASVSAAVGGTVTINCQSSKNVYNNNWLSW
FQQKPGQPPKLLIYYASTLA SGVPSRFRGSGSGTQFTLTISDVQCDDAATYYCAGDYSSS
SDNGFGGGTEVVVKGDPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTTQ
TTGIENSKTPQNSADCTYN LSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
[0063] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 25, 14C12)
METGLRWLLLVAVLKGVHCQSVEESGGRLVTPGTPLTLTCTASGFSRSSYDMSWVRQAP
GKGLEWVGVISTAYNSHYASWAKGRFTISRTSTTVDLKMTSLTTEDTATYFCARGGSWLDL
WGQGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNG
VRTFPSVRQSSGLYSLSSVV SVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPPE
LLGGPSVFIFPPKPKDTLMISRTPEVTCVWDVSQDDPEVQFTWYINNEQVRTARPPLREQQ
FNSTIRVVSTLPIAHQDWL RGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPP
REELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYNKLSVPTS
EWQRGDVFTCSVMHEALHN HYTQKSISRSPGK.
[0064] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 26, 14C12)
MDXRAPTQLLGLLLLWLPGARCALVMTQTPASVSAAVGGTVTINCQSSQSVYDNDELSWY
QQKPGQPPKLLIYALASKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCQATHYSSD
WYLTFGGGTEVVVKGFPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTTQ
TTGTENSKTPQNSADCTY NLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
[0065] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 27, 020B08)
METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLCTVSGFSLSSYDMTWVRQAPGK
GLEWIGIIYASGTTYYANWAKGRFTISKTSTTVDLKVTSPTIGDTATYFCAREGAGVSMTLW
GPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGV
RTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPPELL
GGPSVFI FPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLR
EQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPP
REELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYNKLSVPTS
EWQRGDVFTCSVMHEALHNHYTQKSIS RSPGK.
[0066] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 28, 020B08)
MDMRAPTQLLGLLLLWLPGARCAYDMTQTPASVEVAVGGTVTIKCQASQSISTYLDWYQQ
KPGQPPKLLIYDASDLASGVPSRFKGSGSGTQFTLTISDLECADAATYYCQQGYTHSNVDN
VFGGGTEVVVKGDPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTG
IENSKTPQNSADCTYNLS STLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
[0067] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 29, 006G05) METGLRWLLLVAVLKGVQCQSVEESGGRLVSPGTPLTLTCTASGFSLSSYDMSWVRQAPG KGLEYIGIISSSGSTYYASWAKGRFTISKTSTTVDLEVTSLTTEDTATYFCSREHAGYSGDTG HLWGPGTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLT NGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTCPPP ELLGGPSVGIGPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLRE QQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPPR EELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYNKLSVPTSE WQRGDVFTCSVMHEALHNHYTQ KSISRSPGK.
[0068] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 30, 006G05) MDMRAPTQLLGLLLLWLPGARCAYDMTQTPASVEVAVGGTVAIKCQASQSVSSYLAWYQQ KPGQPPKPLIYEASMLAAGVSSRFKGSGSGTDFTLTISDLECDDAATYYCQQGYSISDIDNA FGGGTEVVVKGDPVAPTVLLFPPSSDEVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGI ENSKTPQNSADCTYNLS STLTLTSTQYNSHKEYTCKVTQGTTSVVQSFSRKNC.
[0069] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 31 , 96G08) METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLCTVSGIDLSSDGISWVRQAPGK
GLEWIGIISSGGNTYYASWAKGRFTISRTSTTVDLKMTSLTTEDTATYFCARVVGGTYSIWG
QGTLVTVSSASTKGPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVH TFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPE VSSVFIFPPKPDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNST
FRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKD KVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGN TFTCSVLHEGLHNHHTEKSLSH SPGK.
[0070] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 32, 96G08)
MDTRAPTQLLGLLLLWLPGATFAQVLTQTASPVSAPVGGTVTINCOSSQSVYNNDFLSWYQ QKPGQPPKLLIYYASTLASGVPSRFKGSGSGTQFTLTISDLECDDAATYYCTGTYGNSAWY EDAFGGGTEVVVKRTPVAPTVLLFPPSSAELATGTATIVCVANKYFPDGTVTWKVDGITQSS GINNSRTPQNSADCTY NLSSTLTLSSDEYNSHDEYTCQVAQDSGSPVVQSFSRKSC.
[0071] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 33, 95F04) METGLRWLLLVAVLKGVQCQSVEESGGRLVTPGTPLTLTCTVSGIDLSSNAMIWVRQAPRE
GLEWIGAMDSNSRTYYATWAKGRFTISRTSSITVDLKITSPTTEDTATYFCARGDGGSSDYT EMWGPGTLVTVSSASTKGPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLS SGVHTFPAVLQSDLYILSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCIC TVPEVSSVFIFFPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREE
QFNSTFRSVSELPIMHQDWLNGKEFKCIRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKE QMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSN WEAGNTFTCSVLHEGLHNHH TEKSLSHSPGK.
[0072] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 34, 95F04) MDTRAPTQLLGLLLLWLPGATFAQAVVTQTTSPVSAPVGGTVTINCQSSQSVYGNNELSW
YQQKPGQPPKLLIYQASSLASGVPSRFKGSGSGTQFTLTISDLECDDAATYYCLGEYSISAD NHFGGGTEVVVKRTPVAPTVLLFPPSSAELATGTATIVCVANKYFPDGTVTWKVDGITQSS GINNSRTPQNSADCTYN LSSTLTLSDEYNHDEYTCQVAQDSGSPVVQSFSRKSC.
[0073] In some embodiments, the anti-CD83 scFv VH domain comprises the amino acid sequence: (SEQ ID NO: 35)
QVQLVQSGGAVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAAVSYDGSNK YYADFVKGRFTISRDNPKNTLYLQMNSLRADDTAVYYCARRGGLDIWGQGTTVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCAAA.
[0074] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 36) LTQPPPASGTPGQQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYYGNDQRPSGVPD RFSASKSGTSASLAISGLQSEDEAHYYCAAWDGSLNGGVI FGGGTKVTLG.
[0075] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 37) VTQPPSASGTPGQRVTISCSGSSSNIGTNPVNWYQQLPGTAPKLLIYTTDQRPSGVPDRFS GSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGLYVFG TGTKVTVLG.
[0076] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 38)
MTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQRPGQSPQPLIYEVSNRFSGVP DRFSGSGSGTDFTLKISRVQAEDVGVYYCMQSLQLWFTG QGTKVEIKR.
[0077] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 39)
MTQSPLSLPVTLGQPASISCRSSGSLIHSDGNTYLDWFQQRPGQSPRRLIYKVSNRDSGVP DRFSGSGSGTDFTLRISRVEAEDIGVYYCMQATHWPRTFGQ GTKVEIKR.
[0078] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 40)
MTQSPLSLPVTLGQPASISCRSSQSLVDSAGNTFLHWFHQRPGQSPRRLIYKVSNRDSGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGQ GTKVEI KR.
[0079] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 41)
LTQSPLSLPVTLGQPASISCKSSQSLVDSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGQ GTKVEI KR.
[0080] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 42)
MTQSPLSLPVTLGQPASISCRSSQSLVHSDGNMYLNWFQQRPGQSPRRLIYKVSNRDSGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQATQPTWTFGQ GTKLEIKR.
[0081] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 43)
MTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTD FT FT I SSATYYCQQTYQGT KLEI KR .
[0082] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 44)
MTQSPSSLSASVGHPVTITCRASQSLISYLNWYHQKPGKAFKLLIYAASILQSGVPSRFSGS GSGTDFTLTISSLQPENFASYYCQHTDSFPRTFGHGTKVE IKR.
[0083] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 45)
LTQPPSASGTPGQGVTISCRGSTSNIGNNVVNWYQHVPGSAPKLLIWSNIQRPSGIPDRFS GSKSGTSASLAISGLQSEDQAVYYCAVWDDGLAGWVFGGGT TVTVLS.
[0084] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 46)
MTQAPVVSVALEQTVRITCQGDSLAIYYDFWYQHKPGQAPVLVIYGKNNRPSGIPHRFSGS SSNTDSLTITGAQAEDEADYYCNSRDSSGNHWVFGGGTNLT VLG.
[0085] In some embodiments, the anti-CD83 scFv VL domain comprises the amino acid sequence: (SEQ ID NO: 47)
LTQSPLSLPVTLGQPASISCKSNQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVP DRFSGSGSGTDFTLKINRVEAEDVGVYYCMQGTQWPRTFGG QGTKLDIKR.
[0086] In some embodiments, the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 48, VH-GBM01)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
[0087] In some embodiments, the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 49, VH-GBM02) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQHPGKGLEWIGYIFSSGNTNY NPSIKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
[0088] In some embodiments, the anti-CD83 scFv VH domain has been humanize and comprises the amino acid sequence: (SEQ ID NO: 50, VH-GBM03) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
[0089] In some embodiments, the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 51 , VH-GBM04) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARAYG KLGFDYWGQGTLVTVSS.
[0090] In some embodiments, the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 52, VH-GBM05) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTARYYCARAYG KLGFDYWGQGTLVTVSS.
[0091] In some embodiments, the anti-CD83 scFv VH domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 53, VH-GBM06) QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAY GKLGFDYWGQGTLVTVSS.
[0092] In some embodiments, the anti-CD83 scFv VL domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 54, VL-GBM01) QLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYLMKVNSDGSHSKGD Gl PDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVF GSGTKVTVL.
[0093] In some embodiments, the anti-CD83 scFv VL domain has been humanized and comprises the amino acid sequence: (SEQ ID NO: 55, VL-GBM02) LPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIMKVNSDGSHSKGDGI PDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVF GSGTKVTVL.
[0094] The heavy and light chains are optionally separated by a linker. Suitable linkers for scFv antibodies are known in the art. In some embodiments, the linker comprises the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:56).
[0095] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 57) QPVLTQSPSASASLGNSVKITCTLSSQHSTYTIGWYQQHPDKAPKYVMYVNSDGSHSKGD GIPDRFSGSSSGAHRYLSISNIQPEDEADYFCGSSDSSGYVFGSGTQLTVLRAAASSGGGG
SGGGGSGGGGSQPVLTQSPSASASLGNSVKITCTLSSQHSTYTIGWYQQHPDKAPKYVMY VNSDGSHSKGDGIPDRFSGSSSGAHRYLSISNIQPEDEADYFCGSSDSSGYVFGSGTQLTV LRAAA.
[0096] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 58) QVQLKESGPGLVKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQKLEWMGYIFSSGNTN YNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTLVTVSSG
GGGSGGGGSGGGGSQVQLKESGPGINKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQ KLEWMGYIFSSGNTNYNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGF DYWGQGTL VTV.
[0097] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence:
(SEQ ID NO: 59)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSQLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYL MKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVFGSGTK VTVL.
[0098] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 60) QVQLQESGPGINKPSQTLSLTCTVSGFSITTGGYWWTWIRQHPGKGLEWIGYIFSSGNTNY NPSIKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
GSGGGGSGGGGSQLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYL MKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVFGSGTK VTVL.
[0099] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 61)
QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSQLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYL MKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVFGSGTK VTVL.
[0100] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 62) QVQLQESGPGINKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
GSGGGGSGGGGSQLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRYL MKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLOSEDEADYYCGSSDSSGYVFGSGTK VTVL.
[0101] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 63)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTARYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSQLVLTQSPSASASLGASVKLICTLSSQHSTYTIGWHQQQPEKGPRYLM KVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVFGSGTKV TVL.
[0102] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 64)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTLVTVSSGG GGSGGGGSGGGGSQLVLTQSPSASASLGASVKLTCTLSSQHSTYTIGWHQQQPEKGPRY
LMKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCGSSDSSGYVFGSGT KVTVL.
[0103] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 65)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSLPVLTQFPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIM
KVNSDGSHSKGDGIPDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVFGSGTK VTVL.
[0104] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence:
(SEQ ID NO: 66)
QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQHPGKGLEWIGYIFSSGNTNY NPSIKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSLPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIM
KVNSDGSHSKGDGIPDRFMGSSSGADRYLIFSNLQSDDEAEYHCGSSDSSGYVFGSGTKV TVL.
[0105] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 67) QVQLQESGPGLVKPSQTLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGGG
GSGGGGSGGGGSLPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIM KVNSDGSHSKGDGIPDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVFGSGTK VTVL.
[0106] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 68)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYVWVTWIRQPPGKGLEWIGYIFSSGNTN YNPSIKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARAYGKLGFDYWGQGTLVTVSSGG GGSGGGGSGGGGSLPVLTQFPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYI
MKVNSDGSHSKGDGIPDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVFGSGT KVTVL.
[0107] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 69)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRVTISVDTSKNQFSLKLSSVTAADTARYYCARAYGKLGFDYWGQGTLVTVSSGGG GSGGGGSGGGGSLPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYIM KVNSDGSHSKGDGIPDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVFGSGTK VTVL.
[0108] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 70)
QVQLQESGPGLVKPSETLSLTCTVSGFSITTGGYWWTWIRQPPGKGLEWIGYIFSSGNTNY NPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTLVTVSSGG GGSGGGGSGGGGSLPVLTQPPSASALLGASIKLTCTLSSQHSTYTIGWYQQRPGRSPQYI MKVNSDGSHSKGDGIPDRFMGSSSGADRYLTFSNLQSDDEAEYHCGSSDSSGYVFGSGT KVTVL.
[0109] In some embodiments, the anti-CD83 scFv comprises an amino acid sequence: (SEQ ID NO: 71)
QVQLKESGPGLVKPSQSLSLTCSVTGFSITTGGYWWTWIRQFPGQKLEWMGYIFSSGNTN YNPSIKSRISITRDTSKNQFFLQLNSVTTEGDTARYYCARAYGKLGFDYWGQGTLVTVSSG GGGSGGGGSGGGGSQPVLTQSPSASASLGNSVKITCTISSQHSTYTIGWYQQHPDKAPKY VMYVNSDGSHSKGDGIPDRFSGSSSGAHRYLSISNIQPEDEADYFCGSSDSSGYVFGSGT QLTVL.
[0110] It will be appreciated that the CDR sequences and VH and VL sequences disclosed herein with respect to CARs also may be utilized in the context of an antibody, antigen-binding fragment thereof, or antibody-like construct, any of which may be conjugated to an additional moiety (e g., an antibody-drug conjugate).
[0111] The CD83-targeted therapeutic of the present disclosure may be administered by any acceptable route, including parenteral and subcutaneous. Other routes include intravenous, intradermal, intramuscular, intraperitoneal, intranodal and intrasplenic, for example. In exemplary aspects, the therapeutic is provided via systemic (e.g., intravenous) administration. A composition comprising the therapeutic typically is sterile. In certain embodiments, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag, or vial having a stopper pierceable by a hypodermic injection needle, or a prefilled syringe.
[0112] In some embodiments, the method described herein further comprises administration of one or more other therapeutic agents. In this regard, the method optionally comprises administering to the subject a second therapeutic agent selected from the group consisting of a corticosteroid, methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, everolimus, antithymocyte globulin, alemtuzumab, cyclophosphamide, ibrutinib, imatinib, infliximab, etanercept, tocilizumab, alemtuzumab, basiliximab, daclizumab, rituximab, denileukin diftitox, pentostatin, ruxolitinib, belumosudil, abatacept, cyclosporine, thalidomide, halofuginone, hydroxychloroquine, mesenchymal stem cells, type 2 innate lymphoid cells, and regulatory T cells (or any combination thereof, potentially in further combination with other therapeutics).
[0113] The disclosure further provides a method of identifying a subject at risk of developing acute GvHD, the method comprising measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD. Also provided is a method of identifying a subject at risk of developing chronic GvHD, the method comprising measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD. Alternatively or in addition, the method of identifying a subject at risk of developing chronic GvHD comprises measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
[0114] The disclosure further provides a CD83-targeted therapeutic for use in a method of treating an alloimmune or autoimmune condition in a subject, wherein the method comprises measuring CD83 in a population of immune cells from the subject, and administering to the subject the CD83-targeted therapeutic. The disclosure further provides use of a CD83- targeted therapeutic for treating (or reducing the risk of developing or delaying the onset of) an alloimmune or autoimmune condition in a subject, wherein (a) CD83 expression is detected in at least 40% of CD4+ T cells in a population of immune cells from the subject or a CD83 gMFI of at least 740.5 is detected in the population of CD4+ T cells from the subject, (b) CD83 expression is detected in at least 19% of CD19+ B cells in a population of immune cells from the subject or a CD83 gMFI of at least 396 is detected in the population of CD19+ B cells from the subject, or (c) CD83 expression is detected in at least 25% of T helper follicular cells in the immune cell population from the subject or a CD83 gMFI of at least 469 is detected in the population of T helper follicular cells obtained from the subject. In various aspects, the subject has previously received allogeneic hematopoietic cell therapy.
Examples
[0115] Example 1 - CD83 expression on CD4+ T cells is increased upon acute GvHD onset
[0116] Acute GVHD remains a major cause of morbidity and death after allogeneic hematopoietic cell transplantation (alloHCT) for blood cancers and marrow failure syndromes. Acute GVHD is typically diagnosed before day +100 and can affect recipient skin, gastrointestinal tract, and/or the liver. Current prevention strategies, like calcineurin- inhibitors, broadly suppress pathogenic donor T cells that mediate GVHD, but also impair healthy effector T cells and regulatory T cells (Treg) that mediate beneficial graft-versus- leukemia (GVL) and immune tolerance, respectively. As such, standard GVHD prevention offers incomplete protection at best and places alloHCT recipients at risk of disease relapse and opportunistic infections.
[0117] Methods: To measure CD83 expression, peripheral blood (~50-80 mis) was serially drawn at day +21 and then weekly up to day +100, or at time of GVHD symptom onset. Peripheral blood mononuclear cells were purified by density gradient and stained for extracellular CD83 expression by flow cytometry. Using a cutoff for CD83 gMFI on CD4+ T cells of at least 740.5, “high” CD83 expression was identified on the target cell. This threshold can be used as a prognostic indicator for acute GVHD as well as a cut off for therapeutic intervention with CD83 CAR T.
[0118] Results/Conclusion: The results of the study are illustrated in Figures 1A-1 D, 2A- 2B, and 3A-3B. The data described herein establish that CD83 is expressed on alloreactive
T cells at the time of acute GVHD onset. CD83 expression is negligible on Tregs, antileukemia T effectors, or effectors of viral immunity. Anti-CD83 chimeric antigen receptor (CAR) T cells that target CD83 can selectively eliminate pathogenic donor T cells that mediate acute GVHD. The data described herein demonstrate that earlier diagnosis of acute GVHD is associated with even higher CD83 expression. This supports a strategy for administering CD83-targeted therapeutics (e.g., CD83 CAR T cells) which further enhances their potency in the prevention and/or treatment of acute GVHD. Indeed, early, rapid, and comprehensive monitoring of CD83 expression on circulating donor T cells after engraftment can inform the clinical use of CD83 CAR T.
[0119] Importantly, high CD83 expression on circulating donor CD4+ T cells before day + 100 (geometric mean fluorescence intensity (gMFI) >740.5) is associated with significantly reduced overall survival.
[0120] CD83 expression on circulating, donor CD4+ T cells can be used to identify those with acute GVHD and potential risk of death from acute GVHD. Further, targeting CD83- expressing effectors of acute GVHD with CD83 CAR T or CD83-directed therapy offers a selective and effective means of preventing acute GVHD and maintaining graft-versus- leukemia as well as antiviral immunity after alloHCT.
[0121] Example 2: CD83 expression on B cells and T helper follicular cells is increased upon chronic GVHD onset
[0122] Chronic GVHD impacts over 60% of alloHCT recipients, effecting skin, muscle, joints, visceral organs, and the immune system. Chronic GVHD is a substantial source of post-transplant morbidity and death, and can emerge years after alloHCT. Chronic GVHD pathogenesis differs from acute GVHD, in that is consists of a triad of allo/autoantibody production, thymic dysfunction, and systemic fibrosis. While several chronic GVHD therapies are now FDA approved (e.g., ruxolitinib, ibrutinib, and belumosudil), many of these agents have nonselective, off-target toxicities that can cause cytopenias and/or infectious complications. Thus, the development of innovative, selective treatments for chronic GVHD is needed.
[0123] Methods: To measure CD83 expression on autoreactive B cells and Tfh, peripheral blood (~50-80 mis) was serially drawn at day +60-100 and then weekly as clinically indicated, or at time of chronic GVHD symptom onset. Peripheral blood mononuclear cells were purified by density gradient and stained for extracellular CD83 expression by flow cytometry. A gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for circulating B cells and Tfh, respectively. This threshold can
be used as a prognostic indicator for chronic GVHD as well as a cut off for therapeutic intervention with CD83 CAR T.
[0124] Results/Conclusions'. The results of the study are illustrated in Figures 4A-4H, 5A- 5C, and 6A-6B. CD83 is significantly expressed pathogenic, autoreactive B cells and T helper follicular cells (Tfh), but absent from healthy circulating B cells. This selectivity allows precise eradication of pathogenic effectors of chronic GVHD by using anti CD83 CAR T, yet spare cells needed for humoral and cellular immunity. This is a complete and needed departure from standard pharmacologic agents used to treat chronic GVHD.
[0125] A gMFI cutoff of 396 and 469 was used to determine low versus high CD83 expression for circulating B cells and Tfh, respectively. AlloHCT recipients with high CD83 expression on B cells of Tfh after day +100 had a significantly reduced overall survival. Thus, CD83 expression on chronic GVHD effectors offers a therapeutic and prognostic marker of disease, and can inform and guide clinical use of CD83 CAR T.
[0126] CD83 expression on circulating, donor B cells and Tfh can be used to identify those with chronic GVHD and potential risk of death from chronic GVHD. Further, targeting CD83 expressing effectors of chronic GVHD with CD83 CAR T or CD83-directed therapy offers a selective and effective means of preventing chronic GVHD and maintaining graft- versus-leukemia as well as antiviral immunity after alloHCT. The data presented herein show CD83-directed therapy, like CD83 CAR T, avoids broad B cell aplasia as observed with CD19 CAR T.
[0127] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0128] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted.
[0129] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range and each
endpoint, unless otherwise indicated herein, and each separate value and endpoint is incorporated into the specification as if it were individually recited herein.
[0130] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
[0131] Preferred embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. A method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof, the method comprising (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.
2. The method of claim 1, wherein step (a) comprises measuring CD83 protein levels.
3. The method of claim 2, wherein CD83 protein levels are measured by immunohistochemistry (IHC), flow cytometry, or Western blotting.
4. The method of claim 2, wherein CD83 protein levels are measured via Geometric mean fluorescence intensity (gMFI).
5. The method of claim 1, wherein step (a) comprises measuring CD83 RNA levels.
6. The method of claim 5, wherein CD83 RNA is measured via real time polymerase chain reaction (qRT-PCR) or RNA-Sequencing.
7. The method of any one of claims 1-6, wherein the condition is acute graft-versus-host disease (GvHD) and the population of immune cells in step (a) comprises CD4+ T cells.
8. The method of claim 7, wherein step (a) comprises detecting CD83 expression in at least 40% of CD4+ T cells in the population.
9. The method of claim 7, wherein step (a) comprises measuring CD83 using Geometric mean fluorescence intensity (gMFI) and detecting a gMFI of at least 740.5.
10. The method of any one of claims 7-9, wherein the method is performed within 30 days of the subject receiving allogeneic hematopoietic cell transplantation and prior to the onset of acute GvHD symptoms.
11. The method of any one of claims 1-6, wherein the condition is chronic GvHD and the population of immune cells in step (a) comprises CD19+ B cells and/or T helper follicular cells.
12. The method of claim 11 , wherein step (a) comprises detecting CD83 expression in at least 19% of CD19+ B cells in the population.
13. The method of claim 11 , wherein step (a) comprises measuring CD19+ B cell CD83 using Geometric mean fluorescence intensity (gMFI) and detecting a gMFI of at least 396.
14. The method of claim 11 , wherein step (a) comprises detecting CD83 expression in at least 25% of T helper follicular cells in the population.
15. The method of claim 11 , wherein step (a) comprises measuring T helper follicular cell CD83 using Geometric mean fluorescence intensity (gMFI) and detecting a gMFI of at least 469.
16. The method of any one of claims 11-15, wherein the method is performed after 60 days of the subject receiving allogeneic hematopoietic cell transplantation and prior to the onset of chronic GvHD symptoms.
17. The method of any one of claims 1-16, wherein the subject is not suffering from symptoms of GvHD when step (a) is performed.
18. The method of any one of claims 1-6, wherein the condition is systemic lupus erythematosus, multiple sclerosis, sjogren’s syndrome, systemic sclerosis/scleroderma, inflammatory bowel disease, or rheumatoid arthritis.
19. The method of any one of claims 1-18, wherein the CD83-targeted therapeutic is an antibody that binds CD83, an antigen-binding antibody fragment that binds CD83, or an antibody-like construct that binds CD83.
20. The method of any one of claims 1-18, wherein the CD83-targeted therapeutic is an immune effector cell genetically modified to express a chimeric antigen receptor (CAR) polypeptide that selectively binds CD83.
21. The method of claim 20, wherein the immune effector cell is a Natural Killer (NK) cell, a cytotoxic T cell, a regulatory T cell, or an innate lymphoid cell (types 1-3).
22. The method of any one of claims 1-21, wherein the method further comprises administering to the subject a second therapeutic agent selected from the group consisting
of a corticosteroid, methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, everolimus, antithymocyte globulin, alemtuzumab, cyclophosphamide, ibrutinib, imatinib, infliximab, etanercept, tocilizumab, alemtuzumab, basiliximab, daclizumab, rituximab, denileukin diftitox, pentostatin, ruxolitinib, belumosudil, abatacept, cyclosporine, thalidomide, halofuginone, hydroxychloroquine, mesenchymal stem cells, type 2 innate lymphoid cells, and regulatory T cells.
23. A method of identifying a subject at risk of developing acute GvHD, the method comprising measuring CD83 in a population of CD4+ T cells from the subject, wherein the presence of CD83 expression in at least 40% of CD4+ T cells in the population or a gMFI of at least 740.5 in the population of CD4+ T cells indicates that the subject is at risk of developing acute GvHD.
24. A method of identifying a subject at risk of developing chronic GvHD, the method comprising measuring CD83 in a population of CD19+ B cells from the subject, wherein the presence of CD83 expression in at least 19% of CD19+ B cells in the population or a gMFI of at least 396 indicates that the subject is at risk of developing chronic GvHD.
25. A method of identifying a subject at risk of developing chronic GvHD, the method comprising measuring CD83 in a population of T helper follicular cells from the subject, wherein the presence of CD83 expression in at least 25% of T helper follicular cells in the population or a gMFI of at least 469 indicates that the subject is at risk of developing chronic GvHD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163292858P | 2021-12-22 | 2021-12-22 | |
US63/292,858 | 2021-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023122643A1 true WO2023122643A1 (en) | 2023-06-29 |
Family
ID=86903792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/082106 WO2023122643A1 (en) | 2021-12-22 | 2022-12-21 | Cd83 and allo- and autoimmune conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023122643A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186105A2 (en) * | 2014-06-05 | 2015-12-10 | Pontificia Universidad Católica De Chile | Method for producing autologous tolerogenic dendritic cells (toldcs) with specific antigens and use thereof in the production of a drug suitable for the treatment of systemic lupus erythematosus (sle) |
US20200347143A1 (en) * | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
WO2021034689A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
WO2021034684A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
WO2021074449A1 (en) * | 2019-10-17 | 2021-04-22 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compounds for immunomodulation |
-
2022
- 2022-12-21 WO PCT/US2022/082106 patent/WO2023122643A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186105A2 (en) * | 2014-06-05 | 2015-12-10 | Pontificia Universidad Católica De Chile | Method for producing autologous tolerogenic dendritic cells (toldcs) with specific antigens and use thereof in the production of a drug suitable for the treatment of systemic lupus erythematosus (sle) |
US20170196950A1 (en) * | 2014-06-05 | 2017-07-13 | Pontificia Universidad Catolica De Chile | Method for producing autologous tolerogenic dendritic cells (toldcs) with specific antigens and their use in the preparation of a medicament useful for the treatment of systemic lupus erythematosus (sle) |
US20200347143A1 (en) * | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
WO2021034689A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
WO2021034684A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
WO2021074449A1 (en) * | 2019-10-17 | 2021-04-22 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compounds for immunomodulation |
Non-Patent Citations (7)
Title |
---|
CALADO DINIS PEDRO, SASAKI YOSHITERU, GODINHO SUSANA A, PELLERIN ALEX, KÖCHERT KARL, SLECKMAN BARRY P, DE ALBORÁN IGNACIO MORENO, : "The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers", NATURE IMMULOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 13, no. 11, 1 November 2012 (2012-11-01), New York , pages 1092 - 1100, XP093077865, ISSN: 1529-2908, DOI: 10.1038/ni.2418 * |
CORRE E., CARMAGNAT M., BUSSON M., DE LATOUR R. P., ROBIN M., RIBAUD P., TOUBERT A., RABIAN C., SOCIE G.: "Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, IT, vol. 95, no. 6, 1 June 2010 (2010-06-01), IT , pages 1025 - 1029, XP093077861, ISSN: 0390-6078, DOI: 10.3324/haematol.2009.018853 * |
FORCADE EDOUARD, KIM HAESOOK T., CUTLER COREY, WANG KATHY, ALHO ANA C., NIKIFOROW SARAH, HO VINCENT T., KORETH JOHN, ARMAND PHILIP: "Circulating T follicular helper cells with increased function during chronic graft-versus-host disease", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 127, no. 20, 19 May 2016 (2016-05-19), US , pages 2489 - 2497, XP093077864, ISSN: 0006-4971, DOI: 10.1182/blood-2015-12-688895 * |
HAVENAR-DAUGHTON COLIN, REISS SAMANTHA M., CARNATHAN DIANE G., WU JENNIFER E., KENDRIC KAYLA, TORRENTS DE LA PEÑA ALBA, KASTURI SU: "Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 197, no. 3, 1 August 2016 (2016-08-01), US , pages 994 - 1002, XP093077867, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1600320 * |
KRETSCHMER ET AL.: "Activated T cells induce rapid CD 83 expression on B cells by engagement of CD 40", IMMUNOLOGY LETTERS, vol. 136, 28 January 2011 (2011-01-28), pages 221 - 227, XP028370310, DOI: 10.1016/j.imlet.2011.01.013 * |
SHRESTHA ET AL.: "Human CD 83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 130, no. 9, 27 July 2020 (2020-07-27), pages 4652 - 4662, XP055801643, DOI: 10.1172/JCI135754 * |
SURETTE FIONNA A., GUTHMILLER JENNA J., LI LEI, STURTZ ALEXANDRIA J., VIJAY RAHUL, POPE ROSEMARY L., MCCLELLAN BRANDON L., PACK AN: "Extrafollicular CD4 T cell-derived IL-10 functions rapidly and transiently to support anti-Plasmodium humoral immunity", PLOS PATHOGENS, vol. 17, no. e1009288, pages 1 - 21, XP093077816, DOI: 10.1371/journal.ppat.1009288 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230250150A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
JP7303749B2 (en) | Chimeric antigen receptor targeting TIM-1 | |
JP6290751B2 (en) | Methods and compositions for increasing the effectiveness of therapeutic antibodies using NK cell enhancing compounds | |
JP2021176326A (en) | Composition and method for tcr reprogramming using fusion protein | |
JP2019519208A (en) | Anti-CTLA-4 antibody | |
US20220225597A1 (en) | Mouse model for assessing toxicities associated with immunotherapies | |
JP2021512635A (en) | Chimeric antigen receptor targeting the tumor microenvironment | |
US20150086575A1 (en) | B cell surface reactive antibodies | |
JP2020508080A (en) | HLA-DR CAR-T compositions and methods of making and using the same | |
US20230167190A1 (en) | Chimeric antigen receptors targeting cd37 | |
JP2023540444A (en) | therapeutic antibodies | |
US20210268027A1 (en) | Chimeric antigen receptors targeting cd37 and cd19 | |
US20210371476A1 (en) | Affinity-enhanced monmeric streptavidin chimeric antigen receptor (car) | |
CN115003698A (en) | anti-TCR antibody molecules and uses thereof | |
US20230147657A1 (en) | Chimeric antigen receptor specific for human cd45rc and uses thereof | |
WO2023122643A1 (en) | Cd83 and allo- and autoimmune conditions | |
US20230192803A1 (en) | Anti-steap2 chimeric antigen receptors and uses thereof | |
US20240228610A9 (en) | Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2 | |
AU2023225596A1 (en) | Kir3dl3 inhibitors and immune cell activating agents | |
WO2024175657A1 (en) | Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma) | |
WO2024040228A2 (en) | Cd83 binding proteins | |
WO2024035341A1 (en) | Cd30 antigen-binding molecules | |
MXPA06000841A (en) | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22912684 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |